US20220389467A1 - Biosynthetic production of psilocybin and related intermediates in recombinant organisms - Google Patents

Biosynthetic production of psilocybin and related intermediates in recombinant organisms Download PDF

Info

Publication number
US20220389467A1
US20220389467A1 US17/878,858 US202217878858A US2022389467A1 US 20220389467 A1 US20220389467 A1 US 20220389467A1 US 202217878858 A US202217878858 A US 202217878858A US 2022389467 A1 US2022389467 A1 US 2022389467A1
Authority
US
United States
Prior art keywords
seq
recombinant host
amino acid
host organism
psilocybin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/878,858
Inventor
Jacob Michael Vogan
Laura Flatauer Peiffer
James Lee Wade
Tyrone Jacob Yacoub
Kirsten Tang
Rachel Nadine Burnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CB Therapeutics Inc USA
Original Assignee
CB Therapeutics Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CB Therapeutics Inc USA filed Critical CB Therapeutics Inc USA
Priority to US17/878,858 priority Critical patent/US20220389467A1/en
Assigned to CB THERAPEUTICS, INC. reassignment CB THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WADE, James Lee, VOGAN, JACOB MICHAEL, BURNETT, Rachel Nadine, PEIFFER, Laura Flatauer, TANG, KRISTEN, YACOUB, TYRONE JACOB
Publication of US20220389467A1 publication Critical patent/US20220389467A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1085Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083Miscellaneous (1.14.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1003Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007Methyltransferases (general) (2.1.1.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y205/00Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/010543-Deoxy-7-phosphoheptulonate synthase (2.5.1.54)

Definitions

  • the Sequence Listing which is a part of the present disclosure, includes a computer readable form and a written sequence listing comprising nucleotide and/or amino acid sequences of the present invention.
  • the sequence listing information recorded in computer readable form is identical to the written sequence listing.
  • the subject matter of the Sequence Listing is incorporated herein by reference in its entirety.
  • the present invention generally relates to the production of psilocybin and its intermediates (e.g., tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, and psilocin) in a modified heterologous microorganism.
  • psilocybin and its intermediates e.g., tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, and psilocin
  • Mental health problems which may also be referred to as mental illness or psychiatric disorder, are behavioral or mental patterns which impair the functioning of individuals across the world. Psilocybin has been increasingly evaluated for treating mental health problems. Such mental health disorders include: personality disorders, anxiety disorders, major depressions, and various addictions. In contrast to anxiolytic medicines, usage of psilocybin does not lead to physical dependence.
  • the present teachings include a recombinant host organism.
  • the recombinant host organism can include: a plurality of cells transfected by a set of genes for synthesizing psilocybin in the recombinant host organism via at least a first pathway and a second pathway.
  • the recombinant host organism can be a fungal species comprising: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii , and Yarrowia lipolytica .
  • the set of genes can include any combination of a gene selected from a group consisting of PsiD, PsiH, PsiK, and PsiM.
  • PsiD can comprise codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 that encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively;
  • PsiH can comprise codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 that encode for isolated amino acid sequences SEQ ID NO: 17 SEQ ID NO: 18, and SEQ ID NO: 19, respectively;
  • PsiK can comprise codon optimized nucleic acid sequences SEQ ID NO: 7 and SEQ ID NO: 8 that encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively;
  • PsiM can comprises codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 that encode for isolated amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23,
  • the set of genes can express amino acid sequences that increase titers of psilocybin in the plurality of cells.
  • the set of genes can synthesize intermediates of psilocybin, wherein the intermediates comprise: tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, and psilocin.
  • a protein can be heterologous to the plurality of cells and an exogenous substrate, wherein the protein is encoded by codon optimized SEQ ID NO: 36.
  • the carbon source can include at least one of: glucose, galactose, sucrose, fructose, corn syrup, corn steep liquor, ethanol, and molasses.
  • the first pathway can be a shikimate-chorismate pathway and the second pathway can be a L-tryptophan pathway
  • the first pathway can be modified by codon optimized SEQ ID NO: 27, SEQ ID NO. 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 and the second pathway is modified by codon optimized SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
  • the present teaching include a plurality of sequences containing nucleotides or amino acids for producing psilocybin in a recombinant host organism, wherein the plurality of sequences comprise SEQ ID NO: 1-SEQ ID NO: 36.
  • an isolated amino acid sequence comprises SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, wherein SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16 can be at least 50% similar to each other, and wherein SEQ ID NO: 14 is encoded by codon optimized SEQ ID NO: 1, SEQ ID NO: 15 is encoded by codon optimized SEQ ID NO: 2, and SEQ ID NO: 16 is encoded by codon optimized SEQ ID NO: 3.
  • an isolated amino acid sequence comprises at least one of: SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, wherein SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19 are at least 40% similar to each other, and wherein SEQ ID NO: 17 is encoded by codon optimized SEQ ID NO: 4, SEQ ID NO: 18 is encoded by codon optimized SEQ ID NO: 5, and SEQ ID NO: 19 is encoded by codon optimized SEQ ID NO: 6.
  • an isolated amino acid sequence comprises at least one of: SEQ ID NO: 20 and SEQ ID NO: 21, wherein SEQ ID NO: 20 and SEQ ID NO: 21 are at least 85% similar to each other; and wherein SEQ ID NO: 21 is encoded by codon optimized SEQ ID NO: 7 and SEQ ID NO: 22 is encoded by codon optimized SEQ ID NO: 8.
  • an isolated amino acid sequence comprises at least one of: SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, wherein SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26 are at least 55% similar to each other, and wherein SEQ ID NO: 22 is encoded by codon optimized SEQ ID NO: 9, SEQ ID NO: 23 is encoded by codon optimized SEQ ID NO: 10, SEQ ID NO: 24 is encoded by SEQ ID NO: 11, SEQ ID NO: 25 is encoded by SEQ ID NO: 12, and SEQ ID NO: 26 is encoded by SEQ ID NO: 13.
  • the present teachings include a method.
  • the method can include: transfecting a plurality of cells in a recombinant host organism a set of genes for synthesizing psilocybin via at least a first pathway and a second pathway; and increasing titers of psilocybin in the plurality of cells via the set of genes; and synthesizing intermediates of psilocybin via the set of genes.
  • the recombinant host organism can be a fungal species comprising: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii , and Yarrowia lipolytica .
  • the set of genes can include a gene from a group consisting of: PsiD, PsiH, PsiK, and PsiM.
  • PsiD can comprise codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 that encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively;
  • PsiH can comprise codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 that encode for isolated amino acid sequences SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively;
  • PsiK can comprise codon optimized nucleic acid sequences SEQ ID NO: 7 and SEQ ID NO: 8 that encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively;
  • PsiM can comprise codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 that encode for isolated amino acid sequences SEQ ID NO: 22,
  • the carbon source can include at least one of: glucose, galactose, sucrose, fructose, corn syrup, corn steep liquor, ethanol, and molasses.
  • the method can also include an exogenous substrate and a transporter protein.
  • the first pathway can be a shikimate-chorismate pathway modified by codon optimized SEQ ID NO: 27, SEQ ID NO. 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 and the second pathway can be a L-tryptophan pathway modified by codon optimized SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
  • the transporter protein can be encoded by codon optimized SEQ ID NO: 36.
  • the intermediates can include: tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, and psilocin.
  • FIG. 1 depicts a table of amino acids and codon triplets.
  • FIG. 2 depicts a table of genes and enzymes inserted into a recombinant host organism.
  • FIG. 3 depicts the biosynthesis of psilocybin.
  • FIG. 4 - 7 depicts sequence alignments.
  • FIG. 8 depicts endogenous pathways in a host organism.
  • FIG. 9 depicts a scheme to increase metabolic flux through shikimate-chorismate and L-tryptophan pathways.
  • FIG. 10 depicts a heterologous recombinant host organism.
  • FIG. 11 depicts HPLC chromatograms and UV/Vis spectra.
  • amino acids refer to the molecular basis for constructing and assembling proteins, such as enzymes. (See FIG. 1 for a table of amino acids.). Peptide bonds (i.e., polypeptides) are formed between amino acids and assemble three-dimensionally (3-D). The 3-D assembly can influence the properties, function, and conformational dynamics of the protein.
  • the protein may: (i) catalyze reactions as enzymes; (ii) transport vesicles, molecules, and other entities within cells as transporter entities; (iii) provide structure to cells and organisms as protein filaments; (iv) replicate deoxyribonucleic acid (DNA); and (v) coordinate actions of cells as cell signalers.
  • nucleotides refers to the molecular basis for constructing and assembling nucleic acids, such as DNA and ribonucleic acid (RNA).
  • RNA ribonucleic acid
  • purines are adenine (A) and guanine (G).
  • the specific pyrimidines are cytosine (C), uracil (U), and thymine (T). T is found in DNA, whereas U is found in RNA.
  • the genetic code defines the sequence of nucleotide triplets (i.e., codons) for specifying which amino acids are added during protein synthesis.
  • Genes refers to regions of DNA. Amino acid sequences in the proteins, as defined by the sequence of a gene, are encoded in the genetic code.
  • the present invention is directed to biosynthetic production of psilocybin and related intermediates in recombinant organisms.
  • the syntheses of psilocybin and intermediates of psilocybin in a laboratory environment typically involve tedious techniques of organic chemistry. Often reproducibility is elusive and the solvents used during the syntheses of psilocybin and intermediates of psilocybin are environmentally toxic. Decarboxylations, selective methylations, and selective phosphorylations can be difficult to obtain via the techniques of organic chemistry. Further, the yields and purity of the intermediates for obtaining the target molecules can be low using the techniques of organic chemistry, where the starting molecule is L-tryptophan and the target molecule is psilocybin.
  • the systems and method herein disclose more environmentally benign processes which can have higher throughputs (i.e., more robust processes).
  • the systems and methods herein include: (i) growing modified recombinant host cells and thereby yielding a recombinant host organism; (ii) expressing engineered psilocybin biosynthesis genes and enzymes in the recombinant host organism; (iii) producing or synthesizing psilocybin and/or intermediates of psilocybin in the recombinant host organism; (iv) fermenting the recombinant host organism; and (v) isolating the psilocybin and/or intermediates of psilocybin from the recombinant host organism. Endogenous pathways of the recombinant host can be modified by the systems and methods herein to produce high purity psilocybin and/or intermediates of psilocybin.
  • Gene source organisms provide a genetic starting source (i.e., raw gene sequences) which is codon optimized and engineered to function in the recombinant host organisms.
  • the recombinant host organisms include but are not limited to: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii , and Yarrowia lipolytica.
  • genes/enzymes that are inserted or engineered into the recombinant host are PsiD, PsiH, PsiK, and PsiM.
  • a PsiD enzyme which is a decarboxylase (e.g., L-tryptophan decarboxylase) derives from a gene source organism herein— Psilocybe cubensis, Psilocybe cyanescens , and Gymnopilus junonius .
  • the decarboxylase can catalyze the decarboxylation of an aliphatic carboxylic acid (i.e., release carbon dioxide) L-tryptophan to tryptamine and 4-hydroxy-L-tryptophan to 4-hydroxytryptamine, as depicted in FIG. 3 .
  • a PsiH enzyme which is a monooxygenase (e.g., Tryptamine 4-monooxygenase) derives from a gene source organism herein— Psilocybe cubensis, Psilocybe cyanescens , and Gymnopilus junonius .
  • the monooxygenase can catalyze the oxidative hydroxylation of the phenyl ring of tryptamine to 4-hydroxytryptamine, as depicted in FIG. 3 .
  • a PsiK enzyme which is a kinase (e.g., 4-hydroxytryptamine kinase) derives from a gene source organism herein— Psilocybe cubensis and Psilocybe cyanescens .
  • the kinase can catalyze the phosphorylation (i.e., adding O ⁇ P(OH) 2 ) of the phenolic oxygen of 4-hydroxytryptamine to norbaeocystin, as depicted in FIG. 3 .
  • the kinase can also catalyze the phosphorylation of psilocin to psilocybin.
  • a PsiM enzyme which is a methyl transferase (e.g., psilocybin synthase) derives from a gene source organism herein— Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius , and Gymnopilus dilepis .
  • the methyl transferase can catalyze the alkylation (i.e., adding a methyl (CH 3 ) group) of the primary amine in norbaeocystin to baecystin, as depicted in FIG. 3 .
  • Another alkylation can take place where the methyl transferase when the secondary amine of baecystin becomes a tertiary amine of psilocybin, as depicted in FIG. 3 .
  • the engineered PsiD, PsiH, PsiK, and PsiM enzymes act on substrates in the psilocybin biosynthetic pathway to produce intermediates of psilocybin and psilocybin itself.
  • the initial substrate for psilocybin intermediates and psilocybin can be L-tryptophan and/or 4-hydroxy-L-tryptophan.
  • These initial substrates can be produced endogenously in a recombinant host as described and/or provided exogenously to a fermentation involving a recombinant host, whereby the host uptakes the starting substrates to feed into the psilocybin biosynthetic pathway.
  • the recombinant host herein described that is expressing all, one, or multiple combinations of the engineered PsiD, PsiH, PsiK, PsiM genes can produce tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, psilocybin, and psilocin.
  • Psilocybin may be converted to psilocin due to spontaneous dephosphorylation.
  • Psilocin is in turn an intermediate which can be acted on by the PsiK enzyme to produce psilocybin.
  • the amino acid alignments of recombinant PsiD enzymes are presented.
  • Recombinant PsiD enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein.
  • the gene used in the pair wise alignment is the PsiD gene from the fungal species— Psilocybe cubensis, Psilocybe cyanescens , and Gymnopilus junonius .
  • the alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiD gene) as a reference.
  • EBLOSUM62 EMBOSS Needle Pair wise Sequence Alignment statistic
  • Psilocybe cubensis PsiD gene
  • SEQ ID NO: 1 codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively.
  • SEQ ID NO: 14 is Psilocybe cubensis (PsiD gene);
  • SEQ ID NO: 15 is Psilocybe cyanescens (PsiD gene);
  • SEQ ID NO: 16 is Gymnopilus junonius (PsiD gene).
  • the amino acid alignment of recombinant PsiH enzymes are presented.
  • Recombinant PsiH enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein.
  • the gene used in the pair wise alignment is the PsiH gene from the fungal species— Psilocybe cubensis, Psilocybe cyanescens , and Gymnopilus junonius .
  • the alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiH gene) as a reference.
  • EBLOSUM62 EMBOSS Needle Pair wise Sequence Alignment statistic
  • Psilocybe cubensis PsiH gene
  • SEQ ID NO: 4 codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 encode for isolated amino acid sequences SEQ ID NO: 17 SEQ ID NO: 18, and SEQ ID NO: 19, respectively.
  • SEQ ID NO: 17 is Psilocybe cubensis (PsiH gene);
  • SEQ ID NO: 18 is Psilocybe cyanescens (PsiH gene);
  • SEQ ID NO: 19 is Gymnopilus junonius (PsiH gene).
  • the amino acid alignment of recombinant PsiK enzymes are presented.
  • Recombinant PsiK enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein.
  • the gene used in the pair wise alignment is the PsiK gene from the fungal species— Psilocybe cubensis and Psilocybe cyanescens .
  • the alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiK gene) as a reference.
  • EBLOSUM62 EMBOSS Needle Pair wise Sequence Alignment statistic
  • Psilocybe cubensis PsiK gene
  • SEQ ID NO: 7 and SEQ ID NO: 8 encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively.
  • SEQ ID NO: 20 is Psilocybe cubensis (PsiK gene)
  • SEQ ID NO: 21 is Psilocybe cyanescens (PsiK gene).
  • Recombinant PsiM enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein.
  • the gene used in the pair wise alignment is the PsiM gene from the fungal species— Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius , and Gymnopilus dilepis .
  • the alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiM gene) as a reference.
  • EBLOSUM62 EMBOSS Needle Pair wise Sequence Alignment statistic
  • PsiM gene Psilocybe cubensis
  • codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 encode for isolated amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24; SEQ ID NO: 25, and SEQ ID NO: 26, respectively.
  • SEQ ID NO: 22 is Psilocybe cubensis (PsiM gene);
  • SEQ ID NO: 23 is Psilocybe cyanescens (PsiM gene);
  • SEQ ID NO: 24 is Panaeolus cynascens (PsiM gene);
  • SEQ ID NO: 25 is Gymnopilus junonius (PsiM gene), and
  • SEQ ID NO: 26 is Gymnopilus dilepis (PsiM gene).
  • the endogenous pathways of a recombinant host organism produce precursors for the engineered PsiD, PsiH, PsiK, PsiM genes.
  • Pathways relating to chorismate, L-glutamine, and L-serine feed into the endogenous pathway for L-tryptophan production, which a recombinant host organism expressing the psilocybin biosynthetic pathway herein described can use to create tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, psilocin, and psilocybin.
  • the enzymes in the endogenous pathways of the recombinant host organism are encircled in FIG. 8 .
  • Glycolysis and gluconeogenesis in combination with ARO3, ARO4, ARO1, and ARO2 enzymes can be subjected to the depicted precursors at the specified point in the pathway to selectively yield chrorismate.
  • the glutamate biosynthesis pathway in combination with a GLN1 enzyme can be subjected to the depicted precursor at the specified point in the pathway to selectively yield L-glutamine.
  • Glycolysis in combination with SER3, SER33, SER1, and SER2 enzymes can be subjected to the depicted precursors at the specified points in the pathway to selectively yield L-serine.
  • Chorismate and L-glutamine in combination with TRP1, TRP2, TRP3, and TRP4 enzymes can be subjected to the depicted precursors at the specified point to selectively yield (1S,2R)-1-C-indol-3-yl)glycerol 3-phosphate.
  • the addition of L-serine to (1S,2R)-1-C-indol-3-yl)glycerol 3-phosphate in the presence of the TRP1 enzyme can yield L-tryptophan.
  • a scheme to increase metabolic flux through the shikimate-chorismate and L-tryptophan pathways is disclosed.
  • the increased metabolic flux through the shikimate-chorismate and L-tryptophan pathways increases the production of L-tryptophan, a key precursor compound for the production of psilocybin and intermediates of psilocybin.
  • Specific enzymes in the described native pathways are overexpressed. Enzymes subject to allosteric inhibition are mutated and overexpressed to render the enzymes insensitive to feedback mechanisms. Enzymes that consume pathway intermediates for off-pathway compound production are hereby deleted.
  • L-tryptophan production is improved herein by overexpressing a series of enzymes that first increase production of the aromatic compound intermediate, chorismate in a series of enzymatic reactions known as the shikimate pathway.
  • shikimate pathway initial precursors, PEP and E4P are converted into 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP), catalyzed by ARO3 and ARO4 enzymes.
  • DAHP 3-deoxy-D-arabinoheptulosonate 7-phosphate
  • ARO3 enzyme (as encoded by codon optimized SEQ ID NO: 29), and a feedback-resistant mutant ARO4 K229L enzyme (as encoded by codon optimized SEQ ID NO: 30) are described herein and can increase metabolic flux through the pathway.
  • genes that encode key enzymes, ARO1 enzyme (as encoded by codon optimized SEQ ID NO: 27) and ARO2 (as encoded by codon optimized SEQ ID NO: 28) are overexpressed as part of a series of enzymes that can convert DAHP to chorismate.
  • the gene that encodes the Escherichia coli shikimate kinase II (AROL enzyme) can be overexpressed to increase pathway flux from DHAP to chorismate via codon optimized SEQ ID NO: 31.
  • Chorismate as a general precursor compound can be converted specifically to L-tryptophan by overexpressing a series of enzymes in the L-tryptophan pathway.
  • flux through the L-tryptophan pathway can be increased by overexpressing the genes that encode specific enzymes, TRP1 enzyme (as encoded by codon optimized by SEQ ID NO: 32), TRP3 enzyme (as encoded by codon optimized by SEQ ID NO: 34), and TRP4 enzyme (as encoded by codon optimized by SEQ ID NO: 35).
  • TRP1 enzyme as encoded by codon optimized by SEQ ID NO: 32
  • TRP3 enzyme as encoded by codon optimized by SEQ ID NO: 34
  • TRP4 enzyme as encoded by codon optimized by SEQ ID NO: 35.
  • overexpression of the gene that encodes the feedback-resistant mutant of TRP2 S76L enzyme (as encoded by SEQ ID NO: 33) is described herein.
  • Chorismate is a precursor that feeds into the metabolic pathways that produce a variety of aromatic alcohols and aromatic amino acids.
  • the mechanism made operable by systems and methods herein reduce pathway flux into pathways that produce off-pathway targets.
  • the gene that encodes the native enzyme, ARO7 enzyme has been deleted to reduce production of tyrosine and phenylalanine.
  • Genes that encode PDZ1 and PDZ2 enzymes have been deleted to reduce pathway flux through the pABA production pathway.
  • a modified heterologous recombinant host organism is: (i) expressing endogenous pathways for L-tryptophan; (ii) expressing a recombinant version of the TAT2 L-tryptophan importer protein; and (iii) selectively expressing recombinant psilocybin biosynthetic pathway genes.
  • Such a recombinant host can produce tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, psilocin, and psilocybin from L-tryptophan.
  • L-tryptophan can be created by the host through endogenous pathways ( FIG.
  • L-tryptophan may also be fed to the recombinant host organism by media supplementation and up taken by the host expressing the recombinant TAT2 importer protein. Accordingly, contact with the L-tryptophan and the recombinant host organism in the media can selectively direct flux towards psilocybin.
  • Other carbon sources can make contact with the recombinant host organism in the media, wherein the other carbon sources include at least one of: glucose, galactose, sucrose, corn steep liquor, ethanol, fructose, and molasses.
  • the nucleotide and amino acid sequences provided are in the order of the psilocybin pathway: PsiD, PsiH, PsiK, and PsiM genes which encode for the respective enzymes.
  • PsiD enzyme selectively and cleanly catalyzes decarboxylation
  • the PsiH enzyme catalyzes selective hydroxylation at the 4-position of an indole
  • the PsiK enzyme catalyzes selective phosphorylation at the hydroxylated 4-position of an indole
  • the PsiM enzyme catalyzes selective and stepwise methylations of an amine group, respectively.
  • codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively.
  • decarboxylations would require harsh and toxic tin hydrides (e.g., Barton Decarboxylation), as opposed to the selective and clean decarboxylation by the PsiD enzyme in the recombinant host.
  • codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 encode for isolated amino acid sequences SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively.
  • Phenyl group functionalization is often done at high temperatures and pressures, while leading to a mixture of products (e.g., hydroxylations at the 5, 6, and 7 positions of the indole).
  • the regioisomers of the hydroxylated products at the 5, 6, and 7 positions of the indole are structurally distinct from each other, but also structurally similar to each other.
  • the PsiH enzyme catalyzes selective hydroxylation of indole at the 4-position in the recombinant host organism herein at standard room conditions ( ⁇ 25 degrees Celsius at ⁇ 1 atm of atmospheric pressure).
  • the systems and methods herein can produce and increase the titers of the hydroxylated indole at the 4-position within the recombinant organism.
  • a sample can be obtained, which exclusively contains the hydroxylated indole at the 4-position. This is indicative of a more facile procedure for obtaining the hydroxylated indole at the 4-position, in comparison to the techniques of organic chemistry.
  • codon optimized nucleic acid sequences SEQ ID NO: 7 and SEQ ID NO: 8 encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively.
  • Primary amines and indole nitrogen are nucleophilic groups than can compete with phenolic oxygen for phosphorylation.
  • the recombinant host supports the PsiK enzyme catalysis of selective phosphorylation of the phenolic oxygen.
  • the recombinant host and the PsiK enzyme can also catalyze the undoing of de-phosphorylations that yield psilocin.
  • the recombinant host organism and the expressed PsiK gene for encoding the PsiK enzyme can convert psilocin back to the target molecule psilocybin.
  • the recombinant host organism and the expressed PsiK gene for encoding the PsiK enzyme can provide a corrective mechanism to obtain the target molecule psilocybin.
  • codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 encode for isolated amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively.
  • the primary amine when subjected to methyl iodide may get over alkylated to the quaternary amine. Further, the reaction is not selective as monoalklyated and dialkylated products may also be obtained. To further complicate the alkylation, the nitrogen of the indole is sufficiently nucleophilic to perform alkylations.
  • the PsiM enzyme catalyzes selective methylation at the primary amine in the recombinant host organism, which is also stepwise.
  • the first methylation yields norbaeocystin and the second methylation yields psilocybin.
  • the indole nitrogen does not get methylated.
  • SEQ ID NO: 1-SEQ ID NO: 36 of the systems and methods herein aid in increasing titers of psilocybin in the recombinant host organism in comparison to the titers of psilocybin in natural state of the host organism.
  • the mutations at specific points of the pathways above direct flux toward yielding psilocybin in the recombinant host organism.
  • genetically engineered host cells may be any species of yeast herein, including but not limited to any species of Saccharomyces, Candida, Schizosaccharomyces, Yarrowia , etc., which have been genetically altered to produce precursor molecules, intermediate molecules, and psilocybin molecules. Additionally, genetically engineered host cells may be any species of filamentous fungus, including but not limited to any species of Aspergillus , which have been genetically altered to produce precursor molecules, intermediate molecules, and psilocybin molecules.
  • yeast herein for the recombinant host organism include but are not limited to: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii , and Yarrowia lipolytica.
  • the gene sequences from gene source organisms are codon optimized to improve expression using techniques disclosed in U.S. patent application Ser. No. 15/719,430, filed Sep. 28, 2017, entitled “An Isolated Codon Optimized Nucleic Acid”.
  • the gene source organisms can include, but are not limited to: Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius , and Gymnopilus dilepis .
  • DNA sequences are synthesized and cloned using techniques known in the art. Gene expression can be controlled by inducible or constitutive promoter systems using the appropriate expression vectors.
  • Genes are transformed into an organism using standard yeast or fungus transformation methods to generate modified host strains (i.e., the recombinant host organism).
  • the modified strains express genes for: (i) producing L-tryptophan and precursor molecules to L-tryptophan; (ii) increasing an output of L-tryptophan molecules and precursor molecules to L-tryptophan molecules; (iii) increasing the import of exogenous L-tryptophan into the host strain; and (iv) the genes for the psilocybin biosynthetic pathway.
  • fermentations are run to determine if the cell will convert the L-tryptophan into psilocybin.
  • the L-tryptophan and psilocybin pathway genes herein can be integrated into the genome of the cell or maintained as an episomal plasmid.
  • Samples are: (i) prepared and extracted using a combination of fermentation, dissolution, and purification steps; and (ii) analyzed by HPLC for the presence of precursor molecules, intermediate molecules, and psilocybin molecules.
  • the genes which can be expressed to encode for a corresponding enzyme or other type of proteins include but are not limited to: PsiM, PsiH, PsiD, PsiK, TRP1, TRP2 S76L, TRP3, TRP4, ARO1, ARO2, ARO3, ARO4 K229L, and AROL.
  • the PsiM gene is expressed or (overexpressed) to encode for the PsiM enzyme; the PsiH gene is overexpressed to encode for the PsiH enzyme; and so forth.
  • PsiM, PsiH, PsiD, and PsiK genes can derive from: Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius , and Gymnopilus dilepis .
  • TRP1, TRP2 S76L, TRP3, TRP4, AR01, ARO2, ARO3, and ARO4 K229L genes can derive from Saccharomyces cerevisiae .
  • These AROL genes can derive from Escherichia coli .
  • genes are transformed into Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii , and Yarrowia lipolytica .
  • the PsiM, PsiH, PsiD, PsiK, TRP1, TRP2 S76L, TRP3, TRP4, ARO1, ARO2, ARO3, ARO4 K229L, and AROL genes which derive from at least one of: Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius, Gymnopilus dilepis, Saccharomyces cerevisiae , and Escherichia coli can be expressed at the same time. Gene sequences can be determined using the techniques disclosed in U.S. Nonprovisional patent application Ser. No. 16/558,909 filed on Sep. 3, 2019, entitled “Automated Pipeline”.
  • Example 1 Construction of Saccharomyces cerevisiae Platform Strains with Elevated Metabolic Flux Towards L-Tryptophan Via Overexpression of the Feedback Resistant Mutant, ARO4 K229L
  • the optimized ARO4 K229L gene is synthesized using DNA synthesis techniques known in the art.
  • the optimized gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing.
  • the optimized ARO4 K229L gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.
  • PDC5 Deletion of PDC5 is performed by replacement of the PDC5 gene with the URA3 cassette in the recombinant host.
  • the PDC5 URA3 knockout fragment, carrying the marker cassette, URA3, and homologous sequence to the targeted gene, PDC5, can be generated by bipartite PCR amplification.
  • the PCR product is transformed into a recombinant host and transformants can be selected on synthetic URA drop-out media. Further verification of the modification in said strain can be carried out by genome sequencing, and analyzed by the techniques disclosed in U.S. Nonprovisional patent application Ser. No. 16/558,909 filed on Sep. 3, 2019, entitled “Automated Pipeline”.
  • Modified host cells that yield recombinant host cells express engineered psilocybin biosynthesis genes and enzymes. More specifically, the psilocybin-producing strain herein is grown in rich culture media containing yeast extract, peptone and a carbon source of glucose, galactose, sucrose, fructose, corn syrup, corn steep liquor, ethanol, and/or molasses. The recombinant host cells are grown in either shake flasks or fed-batch bioreactors. Fermentation temperatures can range from 25 degrees Celsius to 37 degrees Celsius at a pH range from pH 4 to pH 7.5.
  • Exogenous L-tryptophan can be added to media to supplement the precursor pool for psilocybin production, which can be up taken by strains expressing the TAT2 L-tryptophan importer protein.
  • the strains herein can be harvested during a fermentation period ranging from 12 hours onward from the start of fermentation.
  • an Agilent 1100 series liquid chromatography (LC) system equipped with a HILIC column (Obelisc N, SIELC, Wheeling, Ill. USA) is used.
  • a gradient is used of mobile phase A (ultraviolet (UV) grade H 2 O+0.1% Formic Acid) and mobile phase B (UV grade acetonitrile+0.1% Formic Acid).
  • UV ultraviolet
  • B UV grade acetonitrile+0.1% Formic Acid
  • Compound absorbance is measured at 220 nanometers (nm) and 270 nm wavelength using a diode array detector (DAD) and spectral analysis from 200 nm to 400 nm wavelengths.
  • a 0.1 milligram (mg)/milliliter (mL) analytical standard is made from psilocybin certified reference material (Cayman Chemical Company, USA). Each sample is prepared by diluting fermentation biomass from a recombinant host expressing the engineered psilocybin biosynthesis pathway 1:1 in 100% ethanol and filtered in 0.2 um nanofilter vials. Samples are compared to the psilocybin analytical standard retention time and UV-visible spectra for identification. As depicted in inset A of FIG.
  • a fermentation derived product is obtained which has absorption of 300 au at 220 nm with a retention time of 4.55 minutes in a HPLC chromatogram.
  • the fermentation derived product obtained matches the retention time of the psilocybin analytical standard in the overlaid HPLC chromatograms. This indicates that the fermentation derived product is psilocybin.
  • the UV-visible spectra of the fermentation derived product and the psilocybin analytical standard are identical. This further corroborates that the fermentation derived product is psilocybin.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority from U.S. Provisional Application Ser. No. 62/936,387 filed on Nov. 15, 2019, which is incorporated herein by reference in its entirety.
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • Not Applicable.
  • INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC
  • The Sequence Listing, which is a part of the present disclosure, includes a computer readable form and a written sequence listing comprising nucleotide and/or amino acid sequences of the present invention. The sequence listing information recorded in computer readable form is identical to the written sequence listing. The ASCII text file, entitled “psilocybinseq.text”, was created on Nov. 15, 2019 using PatentIn version 3.5 and is incorporated herein by reference in its entirety. The subject matter of the Sequence Listing is incorporated herein by reference in its entirety.
  • FIELD
  • The present invention generally relates to the production of psilocybin and its intermediates (e.g., tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, and psilocin) in a modified heterologous microorganism.
  • INTRODUCTION
  • Mental health problems, which may also be referred to as mental illness or psychiatric disorder, are behavioral or mental patterns which impair the functioning of individuals across the world. Psilocybin has been increasingly evaluated for treating mental health problems. Such mental health disorders include: personality disorders, anxiety disorders, major depressions, and various addictions. In contrast to anxiolytic medicines, usage of psilocybin does not lead to physical dependence.
  • SUMMARY
  • The present teachings include a recombinant host organism. The recombinant host organism can include: a plurality of cells transfected by a set of genes for synthesizing psilocybin in the recombinant host organism via at least a first pathway and a second pathway. The recombinant host organism can be a fungal species comprising: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii, and Yarrowia lipolytica. The set of genes can include any combination of a gene selected from a group consisting of PsiD, PsiH, PsiK, and PsiM.
  • In accordance with a further aspect, PsiD can comprise codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 that encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively; PsiH can comprise codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 that encode for isolated amino acid sequences SEQ ID NO: 17 SEQ ID NO: 18, and SEQ ID NO: 19, respectively; PsiK can comprise codon optimized nucleic acid sequences SEQ ID NO: 7 and SEQ ID NO: 8 that encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively; and PsiM can comprises codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 that encode for isolated amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24; SEQ ID NO: 25, and SEQ ID NO: 26, respectively.
  • In accordance with a further aspect, the set of genes can express amino acid sequences that increase titers of psilocybin in the plurality of cells.
  • In accordance with a further aspect, the set of genes can synthesize intermediates of psilocybin, wherein the intermediates comprise: tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, and psilocin.
  • In accordance with a further aspect, a protein can be heterologous to the plurality of cells and an exogenous substrate, wherein the protein is encoded by codon optimized SEQ ID NO: 36.
  • In accordance with a further aspect, the carbon source can include at least one of: glucose, galactose, sucrose, fructose, corn syrup, corn steep liquor, ethanol, and molasses.
  • In accordance with another aspect, the first pathway can be a shikimate-chorismate pathway and the second pathway can be a L-tryptophan pathway
  • In accordance with another aspect, the first pathway can be modified by codon optimized SEQ ID NO: 27, SEQ ID NO. 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 and the second pathway is modified by codon optimized SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
  • The present teaching include a plurality of sequences containing nucleotides or amino acids for producing psilocybin in a recombinant host organism, wherein the plurality of sequences comprise SEQ ID NO: 1-SEQ ID NO: 36.
  • In accordance with a further aspect, an isolated amino acid sequence comprises SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, wherein SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16 can be at least 50% similar to each other, and wherein SEQ ID NO: 14 is encoded by codon optimized SEQ ID NO: 1, SEQ ID NO: 15 is encoded by codon optimized SEQ ID NO: 2, and SEQ ID NO: 16 is encoded by codon optimized SEQ ID NO: 3.
  • In accordance with a further aspect, an isolated amino acid sequence comprises at least one of: SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, wherein SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19 are at least 40% similar to each other, and wherein SEQ ID NO: 17 is encoded by codon optimized SEQ ID NO: 4, SEQ ID NO: 18 is encoded by codon optimized SEQ ID NO: 5, and SEQ ID NO: 19 is encoded by codon optimized SEQ ID NO: 6.
  • In accordance with a further aspect, an isolated amino acid sequence comprises at least one of: SEQ ID NO: 20 and SEQ ID NO: 21, wherein SEQ ID NO: 20 and SEQ ID NO: 21 are at least 85% similar to each other; and wherein SEQ ID NO: 21 is encoded by codon optimized SEQ ID NO: 7 and SEQ ID NO: 22 is encoded by codon optimized SEQ ID NO: 8.
  • In accordance with a further aspect, an isolated amino acid sequence comprises at least one of: SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, wherein SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26 are at least 55% similar to each other, and wherein SEQ ID NO: 22 is encoded by codon optimized SEQ ID NO: 9, SEQ ID NO: 23 is encoded by codon optimized SEQ ID NO: 10, SEQ ID NO: 24 is encoded by SEQ ID NO: 11, SEQ ID NO: 25 is encoded by SEQ ID NO: 12, and SEQ ID NO: 26 is encoded by SEQ ID NO: 13.
  • The present teachings include a method. The method can include: transfecting a plurality of cells in a recombinant host organism a set of genes for synthesizing psilocybin via at least a first pathway and a second pathway; and increasing titers of psilocybin in the plurality of cells via the set of genes; and synthesizing intermediates of psilocybin via the set of genes. The recombinant host organism can be a fungal species comprising: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii, and Yarrowia lipolytica. The The set of genes can include a gene from a group consisting of: PsiD, PsiH, PsiK, and PsiM.
  • In accordance with a further aspect, PsiD can comprise codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 that encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively; wherein PsiH can comprise codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 that encode for isolated amino acid sequences SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively; wherein PsiK can comprise codon optimized nucleic acid sequences SEQ ID NO: 7 and SEQ ID NO: 8 that encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively; and wherein PsiM can comprise codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 that encode for isolated amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24; SEQ ID NO: 25, and SEQ ID NO: 26, respectively.
  • In accordance with a further aspect, the carbon source can include at least one of: glucose, galactose, sucrose, fructose, corn syrup, corn steep liquor, ethanol, and molasses.
  • In accordance with a further aspect, the method can also include an exogenous substrate and a transporter protein.
  • In accordance with a further aspect, the first pathway can be a shikimate-chorismate pathway modified by codon optimized SEQ ID NO: 27, SEQ ID NO. 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 and the second pathway can be a L-tryptophan pathway modified by codon optimized SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
  • In accordance with a further aspect, the transporter protein can be encoded by codon optimized SEQ ID NO: 36.
  • In accordance with a further aspect, the intermediates can include: tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, and psilocin.
  • These and other features, aspects, and advantages of the present teachings will become better understood with reference to the following description, examples and appended claims.
  • DRAWINGS
  • Those of skill in the art will understand that the drawings, described below, are for illustrative purposes only. The drawings are not intended to limit the scope of the present teachings in any way.
  • FIG. 1 depicts a table of amino acids and codon triplets.
  • FIG. 2 depicts a table of genes and enzymes inserted into a recombinant host organism.
  • FIG. 3 depicts the biosynthesis of psilocybin.
  • FIG. 4-7 depicts sequence alignments.
  • FIG. 8 depicts endogenous pathways in a host organism.
  • FIG. 9 depicts a scheme to increase metabolic flux through shikimate-chorismate and L-tryptophan pathways.
  • FIG. 10 depicts a heterologous recombinant host organism.
  • FIG. 11 depicts HPLC chromatograms and UV/Vis spectra.
  • DETAILED DESCRIPTION Abbreviations and Definitions
  • To facilitate understanding of the invention, a number of terms and abbreviations as used herein are defined below as follows:
  • Amino acids: As used herein, the term “amino acids” refer to the molecular basis for constructing and assembling proteins, such as enzymes. (See FIG. 1 for a table of amino acids.). Peptide bonds (i.e., polypeptides) are formed between amino acids and assemble three-dimensionally (3-D). The 3-D assembly can influence the properties, function, and conformational dynamics of the protein. Within biological systems, the protein may: (i) catalyze reactions as enzymes; (ii) transport vesicles, molecules, and other entities within cells as transporter entities; (iii) provide structure to cells and organisms as protein filaments; (iv) replicate deoxyribonucleic acid (DNA); and (v) coordinate actions of cells as cell signalers.
  • Nucleotides: As used herein, the term “nucleotides” refers to the molecular basis for constructing and assembling nucleic acids, such as DNA and ribonucleic acid (RNA). There are two types of nucleotides—purines and pyrimidines. The specific purines are adenine (A) and guanine (G). The specific pyrimidines are cytosine (C), uracil (U), and thymine (T). T is found in DNA, whereas U is found in RNA. The genetic code defines the sequence of nucleotide triplets (i.e., codons) for specifying which amino acids are added during protein synthesis.
  • Genes: As used herein, the term “genes” refers to regions of DNA. Amino acid sequences in the proteins, as defined by the sequence of a gene, are encoded in the genetic code.
  • The present invention is directed to biosynthetic production of psilocybin and related intermediates in recombinant organisms. The syntheses of psilocybin and intermediates of psilocybin in a laboratory environment typically involve tedious techniques of organic chemistry. Often reproducibility is elusive and the solvents used during the syntheses of psilocybin and intermediates of psilocybin are environmentally toxic. Decarboxylations, selective methylations, and selective phosphorylations can be difficult to obtain via the techniques of organic chemistry. Further, the yields and purity of the intermediates for obtaining the target molecules can be low using the techniques of organic chemistry, where the starting molecule is L-tryptophan and the target molecule is psilocybin.
  • The systems and method herein disclose more environmentally benign processes which can have higher throughputs (i.e., more robust processes). The systems and methods herein include: (i) growing modified recombinant host cells and thereby yielding a recombinant host organism; (ii) expressing engineered psilocybin biosynthesis genes and enzymes in the recombinant host organism; (iii) producing or synthesizing psilocybin and/or intermediates of psilocybin in the recombinant host organism; (iv) fermenting the recombinant host organism; and (v) isolating the psilocybin and/or intermediates of psilocybin from the recombinant host organism. Endogenous pathways of the recombinant host can be modified by the systems and methods herein to produce high purity psilocybin and/or intermediates of psilocybin.
  • Reference is made to the figures to further describe the systems and methods disclosed herein.
  • Referring to FIG. 2 , a table lists the enzymes involved in the direct biosynthesis of psilocybin and psilocybin intermediates in species of fungus (i.e., mushrooms). Gene source organisms provide a genetic starting source (i.e., raw gene sequences) which is codon optimized and engineered to function in the recombinant host organisms. The recombinant host organisms include but are not limited to: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii, and Yarrowia lipolytica.
  • Further, the genes/enzymes that are inserted or engineered into the recombinant host are PsiD, PsiH, PsiK, and PsiM.
  • A PsiD enzyme, which is a decarboxylase (e.g., L-tryptophan decarboxylase) derives from a gene source organism herein—Psilocybe cubensis, Psilocybe cyanescens, and Gymnopilus junonius. The decarboxylase can catalyze the decarboxylation of an aliphatic carboxylic acid (i.e., release carbon dioxide) L-tryptophan to tryptamine and 4-hydroxy-L-tryptophan to 4-hydroxytryptamine, as depicted in FIG. 3 .
  • A PsiH enzyme, which is a monooxygenase (e.g., Tryptamine 4-monooxygenase) derives from a gene source organism herein—Psilocybe cubensis, Psilocybe cyanescens, and Gymnopilus junonius. The monooxygenase can catalyze the oxidative hydroxylation of the phenyl ring of tryptamine to 4-hydroxytryptamine, as depicted in FIG. 3 .
  • A PsiK enzyme, which is a kinase (e.g., 4-hydroxytryptamine kinase) derives from a gene source organism herein—Psilocybe cubensis and Psilocybe cyanescens. The kinase can catalyze the phosphorylation (i.e., adding O═P(OH)2) of the phenolic oxygen of 4-hydroxytryptamine to norbaeocystin, as depicted in FIG. 3 . The kinase can also catalyze the phosphorylation of psilocin to psilocybin.
  • A PsiM enzyme, which is a methyl transferase (e.g., psilocybin synthase) derives from a gene source organism herein—Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius, and Gymnopilus dilepis. The methyl transferase can catalyze the alkylation (i.e., adding a methyl (CH3) group) of the primary amine in norbaeocystin to baecystin, as depicted in FIG. 3 . Another alkylation can take place where the methyl transferase when the secondary amine of baecystin becomes a tertiary amine of psilocybin, as depicted in FIG. 3 .
  • As depicted in FIG. 3 , the engineered PsiD, PsiH, PsiK, and PsiM enzymes act on substrates in the psilocybin biosynthetic pathway to produce intermediates of psilocybin and psilocybin itself. The initial substrate for psilocybin intermediates and psilocybin can be L-tryptophan and/or 4-hydroxy-L-tryptophan. These initial substrates can be produced endogenously in a recombinant host as described and/or provided exogenously to a fermentation involving a recombinant host, whereby the host uptakes the starting substrates to feed into the psilocybin biosynthetic pathway. The recombinant host herein described that is expressing all, one, or multiple combinations of the engineered PsiD, PsiH, PsiK, PsiM genes can produce tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, psilocybin, and psilocin. Psilocybin may be converted to psilocin due to spontaneous dephosphorylation. Psilocin is in turn an intermediate which can be acted on by the PsiK enzyme to produce psilocybin.
  • As depicted in FIG. 4 , the amino acid alignments of recombinant PsiD enzymes are presented. Recombinant PsiD enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein. The gene used in the pair wise alignment is the PsiD gene from the fungal species—Psilocybe cubensis, Psilocybe cyanescens, and Gymnopilus junonius. The alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiD gene) as a reference. The identity percentage and similarity percentage of the amino acid sequences are presented.
  • For the PsiD gene, codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively. SEQ ID NO: 14 is Psilocybe cubensis (PsiD gene); SEQ ID NO: 15 is Psilocybe cyanescens (PsiD gene); and SEQ ID NO: 16 is Gymnopilus junonius (PsiD gene).
  • As depicted in FIG. 5 , the amino acid alignment of recombinant PsiH enzymes are presented. Recombinant PsiH enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein. The gene used in the pair wise alignment is the PsiH gene from the fungal species—Psilocybe cubensis, Psilocybe cyanescens, and Gymnopilus junonius. The alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiH gene) as a reference. The identity percentage and similarity percentage of the amino acid sequences are presented.
  • For the PsiH gene, codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 encode for isolated amino acid sequences SEQ ID NO: 17 SEQ ID NO: 18, and SEQ ID NO: 19, respectively. SEQ ID NO: 17 is Psilocybe cubensis (PsiH gene); SEQ ID NO: 18 is Psilocybe cyanescens (PsiH gene); and SEQ ID NO: 19 is Gymnopilus junonius (PsiH gene).
  • As depicted in FIG. 6 , the amino acid alignment of recombinant PsiK enzymes are presented. Recombinant PsiK enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein. The gene used in the pair wise alignment is the PsiK gene from the fungal species—Psilocybe cubensis and Psilocybe cyanescens. The alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiK gene) as a reference. The identity percentage and similarity percentage of the amino acid sequences are presented.
  • For the PsiK gene, codon optimized nucleic acid sequences SEQ ID NO: 7 and SEQ ID NO: 8 encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively. SEQ ID NO: 20 is Psilocybe cubensis (PsiK gene) and SEQ ID NO: 21 is Psilocybe cyanescens (PsiK gene).
  • As depicted in FIG. 7 , the amino acid alignment of recombinant PsiM enzymes are presented. Recombinant PsiM enzymes have been reengineered from various fungal species to function in heterologous recombinant host organisms herein. The gene used in the pair wise alignment is the PsiM gene from the fungal species—Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius, and Gymnopilus dilepis. The alignment is performed with EMBOSS Needle Pair wise Sequence Alignment statistic (EBLOSUM62) with Psilocybe cubensis (PsiM gene) as a reference. The identity percentage and similarity percentage of the amino acid sequences are presented.
  • For the PsiM gene, codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 encode for isolated amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24; SEQ ID NO: 25, and SEQ ID NO: 26, respectively. SEQ ID NO: 22 is Psilocybe cubensis (PsiM gene); SEQ ID NO: 23 is Psilocybe cyanescens (PsiM gene); SEQ ID NO: 24 is Panaeolus cynascens (PsiM gene); SEQ ID NO: 25 is Gymnopilus junonius (PsiM gene), and SEQ ID NO: 26 is Gymnopilus dilepis (PsiM gene).
  • As depicted in FIG. 8 , the endogenous pathways of a recombinant host organism produce precursors for the engineered PsiD, PsiH, PsiK, PsiM genes. Pathways relating to chorismate, L-glutamine, and L-serine, feed into the endogenous pathway for L-tryptophan production, which a recombinant host organism expressing the psilocybin biosynthetic pathway herein described can use to create tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, psilocin, and psilocybin. The enzymes in the endogenous pathways of the recombinant host organism are encircled in FIG. 8 . Glycolysis and gluconeogenesis in combination with ARO3, ARO4, ARO1, and ARO2 enzymes can be subjected to the depicted precursors at the specified point in the pathway to selectively yield chrorismate. The glutamate biosynthesis pathway in combination with a GLN1 enzyme can be subjected to the depicted precursor at the specified point in the pathway to selectively yield L-glutamine. Glycolysis in combination with SER3, SER33, SER1, and SER2 enzymes can be subjected to the depicted precursors at the specified points in the pathway to selectively yield L-serine. Chorismate and L-glutamine in combination with TRP1, TRP2, TRP3, and TRP4 enzymes can be subjected to the depicted precursors at the specified point to selectively yield (1S,2R)-1-C-indol-3-yl)glycerol 3-phosphate. The addition of L-serine to (1S,2R)-1-C-indol-3-yl)glycerol 3-phosphate in the presence of the TRP1 enzyme can yield L-tryptophan.
  • As depicted in FIG. 9 , a scheme to increase metabolic flux through the shikimate-chorismate and L-tryptophan pathways is disclosed. The increased metabolic flux through the shikimate-chorismate and L-tryptophan pathways increases the production of L-tryptophan, a key precursor compound for the production of psilocybin and intermediates of psilocybin. Specific enzymes in the described native pathways are overexpressed. Enzymes subject to allosteric inhibition are mutated and overexpressed to render the enzymes insensitive to feedback mechanisms. Enzymes that consume pathway intermediates for off-pathway compound production are hereby deleted.
  • L-tryptophan production is improved herein by overexpressing a series of enzymes that first increase production of the aromatic compound intermediate, chorismate in a series of enzymatic reactions known as the shikimate pathway. As described in FIG. 5 , the shikimate-chorismate pathway initial precursors, PEP and E4P are converted into 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP), catalyzed by ARO3 and ARO4 enzymes.
  • Overexpression of the genes encoding ARO3 enzyme (as encoded by codon optimized SEQ ID NO: 29), and a feedback-resistant mutant ARO4 K229L enzyme (as encoded by codon optimized SEQ ID NO: 30) are described herein and can increase metabolic flux through the pathway. In addition, genes that encode key enzymes, ARO1 enzyme (as encoded by codon optimized SEQ ID NO: 27) and ARO2 (as encoded by codon optimized SEQ ID NO: 28) are overexpressed as part of a series of enzymes that can convert DAHP to chorismate. In addition, the gene that encodes the Escherichia coli shikimate kinase II (AROL enzyme) can be overexpressed to increase pathway flux from DHAP to chorismate via codon optimized SEQ ID NO: 31.
  • Chorismate as a general precursor compound can be converted specifically to L-tryptophan by overexpressing a series of enzymes in the L-tryptophan pathway. As described in FIG. 9 , flux through the L-tryptophan pathway can be increased by overexpressing the genes that encode specific enzymes, TRP1 enzyme (as encoded by codon optimized by SEQ ID NO: 32), TRP3 enzyme (as encoded by codon optimized by SEQ ID NO: 34), and TRP4 enzyme (as encoded by codon optimized by SEQ ID NO: 35). Furthermore, overexpression of the gene that encodes the feedback-resistant mutant of TRP2 S76L enzyme (as encoded by SEQ ID NO: 33) is described herein.
  • Chorismate is a precursor that feeds into the metabolic pathways that produce a variety of aromatic alcohols and aromatic amino acids. The mechanism made operable by systems and methods herein reduce pathway flux into pathways that produce off-pathway targets. As described in FIG. 9 , genes that encode native enzymes—PDC5 enzyme and ARO10 enzyme—have been deleted to reduce pathway flux through the pathways that produce aromatic alcohols. The gene that encodes the native enzyme, ARO7 enzyme has been deleted to reduce production of tyrosine and phenylalanine. Genes that encode PDZ1 and PDZ2 enzymes have been deleted to reduce pathway flux through the pABA production pathway.
  • As depicted in FIG. 10 , a modified heterologous recombinant host organism is: (i) expressing endogenous pathways for L-tryptophan; (ii) expressing a recombinant version of the TAT2 L-tryptophan importer protein; and (iii) selectively expressing recombinant psilocybin biosynthetic pathway genes. Such a recombinant host can produce tryptamine, 4-hydroxytryptamine, norbaeocystin, baeocystin, psilocin, and psilocybin from L-tryptophan. L-tryptophan can be created by the host through endogenous pathways (FIG. 8 ) or engineered pathways (FIG. 9 ). L-tryptophan may also be fed to the recombinant host organism by media supplementation and up taken by the host expressing the recombinant TAT2 importer protein. Accordingly, contact with the L-tryptophan and the recombinant host organism in the media can selectively direct flux towards psilocybin. Other carbon sources can make contact with the recombinant host organism in the media, wherein the other carbon sources include at least one of: glucose, galactose, sucrose, corn steep liquor, ethanol, fructose, and molasses.
  • Besides the recombinant TAT2 importer protein, which is encoded by a codon optimized L-tryptophan importer (SEQ ID NO: 36), the nucleotide and amino acid sequences provided are in the order of the psilocybin pathway: PsiD, PsiH, PsiK, and PsiM genes which encode for the respective enzymes. In the systems and methods herein, PsiD enzyme selectively and cleanly catalyzes decarboxylation; the PsiH enzyme catalyzes selective hydroxylation at the 4-position of an indole; the PsiK enzyme catalyzes selective phosphorylation at the hydroxylated 4-position of an indole; and the PsiM enzyme catalyzes selective and stepwise methylations of an amine group, respectively.
  • By expressing the PsiD gene in the recombinant host organism, codon optimized nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 encode for isolated amino acid sequences SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively. Using the techniques of organic chemistry, decarboxylations would require harsh and toxic tin hydrides (e.g., Barton Decarboxylation), as opposed to the selective and clean decarboxylation by the PsiD enzyme in the recombinant host.
  • By expressing the PsiH gene in the recombinant host organism, codon optimized nucleic acid sequences SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 encode for isolated amino acid sequences SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively. Phenyl group functionalization is often done at high temperatures and pressures, while leading to a mixture of products (e.g., hydroxylations at the 5, 6, and 7 positions of the indole). The regioisomers of the hydroxylated products at the 5, 6, and 7 positions of the indole are structurally distinct from each other, but also structurally similar to each other. Separation of such regioisomers can be very challenging and requires cumbersome separation techniques (e.g., slow column chromatography with poor separation (i.e., the regiosiomers have similar Rf values to each other) and low accompanying yields). In contrast, the PsiH enzyme catalyzes selective hydroxylation of indole at the 4-position in the recombinant host organism herein at standard room conditions (˜25 degrees Celsius at ˜1 atm of atmospheric pressure). The systems and methods herein can produce and increase the titers of the hydroxylated indole at the 4-position within the recombinant organism. Using the purification techniques, as described in more detail with respect to the Examples, a sample can be obtained, which exclusively contains the hydroxylated indole at the 4-position. This is indicative of a more facile procedure for obtaining the hydroxylated indole at the 4-position, in comparison to the techniques of organic chemistry.
  • By expressing the PsiK gene in the recombinant host organism, codon optimized nucleic acid sequences SEQ ID NO: 7 and SEQ ID NO: 8 encode for isolated amino acid sequences SEQ ID NO: 20 and SEQ ID NO: 21, respectively. Primary amines and indole nitrogen are nucleophilic groups than can compete with phenolic oxygen for phosphorylation. In contrast, the recombinant host supports the PsiK enzyme catalysis of selective phosphorylation of the phenolic oxygen. The recombinant host and the PsiK enzyme can also catalyze the undoing of de-phosphorylations that yield psilocin. Stated another way, the recombinant host organism and the expressed PsiK gene for encoding the PsiK enzyme can convert psilocin back to the target molecule psilocybin. Stated yet another way, the recombinant host organism and the expressed PsiK gene for encoding the PsiK enzyme can provide a corrective mechanism to obtain the target molecule psilocybin.
  • By expressing the PsiM gene in the recombinant host organism, codon optimized nucleic acid sequences SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, and SEQ ID NO: 13 encode for isolated amino acid sequences SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively. The primary amine when subjected to methyl iodide may get over alkylated to the quaternary amine. Further, the reaction is not selective as monoalklyated and dialkylated products may also be obtained. To further complicate the alkylation, the nitrogen of the indole is sufficiently nucleophilic to perform alkylations. In contrast, the PsiM enzyme catalyzes selective methylation at the primary amine in the recombinant host organism, which is also stepwise. The first methylation yields norbaeocystin and the second methylation yields psilocybin. The indole nitrogen does not get methylated.
  • SEQ ID NO: 1-SEQ ID NO: 36 of the systems and methods herein aid in increasing titers of psilocybin in the recombinant host organism in comparison to the titers of psilocybin in natural state of the host organism. As described above, the mutations at specific points of the pathways above direct flux toward yielding psilocybin in the recombinant host organism.
  • EXAMPLES
  • Aspects of the present teachings may be further understood in light of the following examples, which should not be construed as limiting the scope of the present teachings in any way.
  • The following examples are provided to illustrate various aspects of the present invention. They are not intended to limit the invention, which is defined by the accompanying claims.
  • In the examples below, genetically engineered host cells may be any species of yeast herein, including but not limited to any species of Saccharomyces, Candida, Schizosaccharomyces, Yarrowia, etc., which have been genetically altered to produce precursor molecules, intermediate molecules, and psilocybin molecules. Additionally, genetically engineered host cells may be any species of filamentous fungus, including but not limited to any species of Aspergillus, which have been genetically altered to produce precursor molecules, intermediate molecules, and psilocybin molecules. Some of the species of yeast herein for the recombinant host organism include but are not limited to: Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii, and Yarrowia lipolytica.
  • The gene sequences from gene source organisms are codon optimized to improve expression using techniques disclosed in U.S. patent application Ser. No. 15/719,430, filed Sep. 28, 2017, entitled “An Isolated Codon Optimized Nucleic Acid”. The gene source organisms can include, but are not limited to: Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius, and Gymnopilus dilepis. DNA sequences are synthesized and cloned using techniques known in the art. Gene expression can be controlled by inducible or constitutive promoter systems using the appropriate expression vectors. Genes are transformed into an organism using standard yeast or fungus transformation methods to generate modified host strains (i.e., the recombinant host organism). The modified strains express genes for: (i) producing L-tryptophan and precursor molecules to L-tryptophan; (ii) increasing an output of L-tryptophan molecules and precursor molecules to L-tryptophan molecules; (iii) increasing the import of exogenous L-tryptophan into the host strain; and (iv) the genes for the psilocybin biosynthetic pathway. In the presence or absence of exogenous L-tryptophan, fermentations are run to determine if the cell will convert the L-tryptophan into psilocybin. The L-tryptophan and psilocybin pathway genes herein can be integrated into the genome of the cell or maintained as an episomal plasmid. Samples are: (i) prepared and extracted using a combination of fermentation, dissolution, and purification steps; and (ii) analyzed by HPLC for the presence of precursor molecules, intermediate molecules, and psilocybin molecules.
  • Using the systems and methods herein, the genes which can be expressed to encode for a corresponding enzyme or other type of proteins include but are not limited to: PsiM, PsiH, PsiD, PsiK, TRP1, TRP2 S76L, TRP3, TRP4, ARO1, ARO2, ARO3, ARO4 K229L, and AROL. For example, the PsiM gene is expressed or (overexpressed) to encode for the PsiM enzyme; the PsiH gene is overexpressed to encode for the PsiH enzyme; and so forth. These PsiM, PsiH, PsiD, and PsiK genes can derive from: Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius, and Gymnopilus dilepis. These TRP1, TRP2 S76L, TRP3, TRP4, AR01, ARO2, ARO3, and ARO4 K229L genes can derive from Saccharomyces cerevisiae. These AROL genes can derive from Escherichia coli. Further, these genes are transformed into Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii, and Yarrowia lipolytica. The PsiM, PsiH, PsiD, PsiK, TRP1, TRP2 S76L, TRP3, TRP4, ARO1, ARO2, ARO3, ARO4 K229L, and AROL genes which derive from at least one of: Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cynascens, Gymnopilus junonius, Gymnopilus dilepis, Saccharomyces cerevisiae, and Escherichia coli can be expressed at the same time. Gene sequences can be determined using the techniques disclosed in U.S. Nonprovisional patent application Ser. No. 16/558,909 filed on Sep. 3, 2019, entitled “Automated Pipeline”.
  • Example 1—Construction of Saccharomyces cerevisiae Platform Strains with Elevated Metabolic Flux Towards L-Tryptophan Via Overexpression of the Feedback Resistant Mutant, ARO4 K229L
  • The optimized ARO4 K229L gene is synthesized using DNA synthesis techniques known in the art. The optimized gene can be cloned into vectors with the proper regulatory elements for gene expression (e.g. promoter, terminator) and the derived plasmid can be confirmed by DNA sequencing. As an alternative to expression from an episomal plasmid, the optimized ARO4 K229L gene is inserted into the recombinant host genome. Integration is achieved by a single cross-over insertion event of the plasmid. Strains with the integrated gene can be screened by rescue of auxotrophy and genome sequencing.
  • Example 2—Construction of Saccharomyces cerevisiae Platform Strains with Elevated Metabolic Flux Towards L-Tryptophan Via Deletion of PDC5
  • Deletion of PDC5 is performed by replacement of the PDC5 gene with the URA3 cassette in the recombinant host. The PDC5 URA3 knockout fragment, carrying the marker cassette, URA3, and homologous sequence to the targeted gene, PDC5, can be generated by bipartite PCR amplification. The PCR product is transformed into a recombinant host and transformants can be selected on synthetic URA drop-out media. Further verification of the modification in said strain can be carried out by genome sequencing, and analyzed by the techniques disclosed in U.S. Nonprovisional patent application Ser. No. 16/558,909 filed on Sep. 3, 2019, entitled “Automated Pipeline”.
  • Example 3—Method of Growth
  • Modified host cells that yield recombinant host cells, such as the psilocybin-producing strain herein, express engineered psilocybin biosynthesis genes and enzymes. More specifically, the psilocybin-producing strain herein is grown in rich culture media containing yeast extract, peptone and a carbon source of glucose, galactose, sucrose, fructose, corn syrup, corn steep liquor, ethanol, and/or molasses. The recombinant host cells are grown in either shake flasks or fed-batch bioreactors. Fermentation temperatures can range from 25 degrees Celsius to 37 degrees Celsius at a pH range from pH 4 to pH 7.5. Exogenous L-tryptophan can be added to media to supplement the precursor pool for psilocybin production, which can be up taken by strains expressing the TAT2 L-tryptophan importer protein. The strains herein can be harvested during a fermentation period ranging from 12 hours onward from the start of fermentation.
  • Example 4—Detection of Isolated Product
  • To identify fermentation derived psilocybin produced by a recombinant host expressing the engineered psilocybin biosynthetic pathway, an Agilent 1100 series liquid chromatography (LC) system equipped with a HILIC column (Obelisc N, SIELC, Wheeling, Ill. USA) is used. A gradient is used of mobile phase A (ultraviolet (UV) grade H2O+0.1% Formic Acid) and mobile phase B (UV grade acetonitrile+0.1% Formic Acid). Column temperature is set at 40 degree Celsius. Compound absorbance is measured at 220 nanometers (nm) and 270 nm wavelength using a diode array detector (DAD) and spectral analysis from 200 nm to 400 nm wavelengths. A 0.1 milligram (mg)/milliliter (mL) analytical standard is made from psilocybin certified reference material (Cayman Chemical Company, USA). Each sample is prepared by diluting fermentation biomass from a recombinant host expressing the engineered psilocybin biosynthesis pathway 1:1 in 100% ethanol and filtered in 0.2 um nanofilter vials. Samples are compared to the psilocybin analytical standard retention time and UV-visible spectra for identification. As depicted in inset A of FIG. 11 , a fermentation derived product is obtained which has absorption of 300 au at 220 nm with a retention time of 4.55 minutes in a HPLC chromatogram. As depicted in inset B of FIG. 11 , the fermentation derived product obtained matches the retention time of the psilocybin analytical standard in the overlaid HPLC chromatograms. This indicates that the fermentation derived product is psilocybin. As depicted in inset C of FIG. 11 , the UV-visible spectra of the fermentation derived product and the psilocybin analytical standard are identical. This further corroborates that the fermentation derived product is psilocybin.
  • OTHER EMBODIMENTS
  • The detailed description set-forth above is provided to aid those skilled in the art in practicing the present invention. However, the invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed because these embodiments are intended as illustration of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description which does not depart from the spirit or scope of the present inventive discovery. Such modifications are also intended to fall within the scope of the appended claims.
  • REFERENCES CITED
  • All publications, patents, patent applications and other references cited in this application are incorporated herein by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application or other reference was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Citation of a reference herein shall not be construed as an admission that such is prior art to the present invention.
  • SEQUENCE LISTINGS
    (Psilocybe cubensis (PSID gene))
    SEQ ID NO: 1
    ATGCAAGTCATCCCCGCGTGCAACAGCGCAGCTAT
    AAGGTCACTTTGTCCGACCCCCGAGAGCTTTAGAA
    ATATGGGCTGGCTTTCCGTGAGCGATGCCGTCTAT
    AGCGAATTTATAGGTGAACTTGCGACGAGAGCATC
    TAATAGAAACTACAGCAATGAGTTCGGTTTAATGC
    AACCAATACAAGAATTTAAAGCGTTCATCGAGAGT
    GATCCCGTTGTACACCAAGAGTTTATCGACATGTT
    TGAAGGCATCCAAGATTCTCCGAGGAACTACCAAG
    AACTATGTAACATGTTCAATGATATTTTTAGGAAG
    GCTCCCGTATACGGAGATTTGGGCCCTCCGGTCTA
    CATGATTATGGCGAAGTTGATGAATACAAGGGCGG
    GTTTCAGTGCGTTCACAAGACAACGTCTGAACCTG
    CATTTTAAAAAGCTGTTCGATACCTGGGGTTTATT
    TCTTTCATCCAAAGACAGCAGGAATGTCCTGGTAG
    CTGACCAGTTTGATGATAGGCACTGCGGCTGGCTG
    AACGAGAGGGCATTATCTGCGATGGTGAAACACTA
    TAATGGGCGTGCATTTGATGAAGTATTTCTATGTG
    ACAAAAATGCACCCTATTACGGCTTTAATTCATAC
    GACGATTTCTTCAATAGGAGGTTCCGTAATAGAGA
    CATTGATAGACCCGTTGTCGGCGGCGTGAACAACA
    CGACGCTTATATCAGCAGCCTGTGAGTCTCTGTCT
    TATAACGTCAGCTATGACGTGCAATCCTTAGATAC
    TTTAGTTTTCAAAGGTGAGACGTACTCATTAAAAC
    ATCTTTTGAATAATGATCCATTTACGCCACAATTC
    GAGCACGGTTCCATATTGCAAGGATTCCTAAACGT
    GACAGCATATCATCGTTGGCACGCGCCGGTTAACG
    GAACTATCGTCAAGATAATCAACGTTCCTGGTACT
    TATTTCGCACAAGCGCCGTCTACCATCGGTGATCC
    GATCCCAGATAATGACTATGATCCACCGCCATATC
    TAAAGAGTCTTGTGTACTTCAGTAACATTGCAGCG
    AGACAGATTATGTTCATAGAAGCTGATAACAAGGA
    GATAGGCCTAATTTTCCTGGTTTTTATAGGCATGA
    CAGAAATTTCAACGTGTGAAGCAACGGTATCCGAG
    GGGCAACATGTCAATAGAGGGGACGACCTGGGTAT
    GTTTCATTTCGGGGGCTCTTCTTTTGCCCTTGGCC
    TGCGTAAAGACTGCCGTGCCGAAATTGTTGAGAAG
    TTCACGGAGCCCGGGACAGTTATAAGGATTAACGA
    AGTCGTCGCCGCCTTGAAGGCTTAA
    (Psilocybe cyanescens (PSID gene)) 
    SEQ ID NO: 2
    ATGCAAGTGCTTCCTGCTTGCCAAAGCTCTGCCCT
    TAAAACCCTGTGTCCGAGCCCCGAGGCTTTTAGAA
    AGCTGGGATGGCTACCTACGTCTGACGAAGTGTAC
    AACGAGTTCATAGATGATCTGACTGGCAGGACTTG
    CAATGAGAAGTATAGCAGCCAAGTAACCCTGTTAA
    AGCCAATCCAAGACTTCAAGACTTTCATAGAGAAT
    GACCCGATAGTATATCAAGAGTTCATTAGCATGTT
    TGAGGGCATAGAACAGAGCCCTACTAACTATCATG
    AGCTATGTAACATGTTCAACGATATTTTTCGTAAG
    GCACCCCTATACGGAGACTTAGGACCACCTGTCTA
    CATGATAATGGCACGTATTATGAATACGCAGGCGG
    GTTTTTCAGCGTTCACCAAAGAATCTCTGAACTTC
    CATTTTAAGAAGCTATTCGACACGTGGGGTCTATT
    CCTAAGCTCTAAAAATTCCAGAAACGTACTTGTCG
    CCGATCAGTTTGACGACAAACATTACGGATGGTTT
    TCTGAGAGAGCAAAGACTGCGATGATGATCAACTA
    TCCAGGACGTACATTCGAGAAGGTCTTCATCTGTG
    ACGAGCATGTGCCTTATCACGGATTTACTTCCTAT
    GACGACTTCTTTAACAGGAGATTTCGTGACAAGGA
    TACAGACCGTCCCGTCGTCGGTGGCGTCACCGACA
    CGACGTTGATAGGCGCGGCATGTGAAAGTTTATCT
    TATAACGTTTCTCACAACGTCCAATCACTGGACAC
    CCTTGTCATAAAAGGCGAGGCGTACTCTTTAAAAC
    ACCTTCTGCATAATGACCCATTTACGCCACAGTTT
    GAACATGGATCTATCATCCAAGGATTCTTGAACGT
    TACAGCCTATCACAGATGGCACTCTCCAGTTAACG
    GCACTATTGTGAAGATTGTAAACGTACCAGGGACA
    TACTTTGCCCAGGCGCCCTATACCATAGGTAGCCC
    AATCCCTGATAATGACCGGGACCCGCCGCCCTACT
    TGAAGAGCCTTGTTTATTTTAGCAACATTGCTGCC
    AGACAGATTATGTTTATTGAGGCTGACAATAAAGA
    TATTGGCCTTATCTTTCTTGTGTTCATTGGCATGA
    CTGAAATTAGCACATGTGAAGCGACGGTATGCGAA
    GGACAGCACGTTAACAGAGGCGATGACCTTGGGAT
    GTTTCATTTTGGGGGATCGAGTTTTGCATTGGGGC
    TTAGAAAAGATAGCAAAGCAAAAATACTAGAAAAA
    TTTGCAAAGCCGGGAACAGTAATAAGGATTAACGA
    GCTGGTGGCATCCGTCAGAAAATAA
    (Gymnopilus junonius (PSID gene))
    SEQ ID NO: 3
    ATGTCATCTCCTCGTATCGTGCTGCACAGGGTTGG
    TGGCTGGCTGCCTAAAGACCAAAACGTGCTAGAAG
    CATGGCTGAGCAAGAAGATTGCTAAAGCAAAAACT
    AGAAATAGGGCTCCAAAAGATTGGGCTCCTGTGAT
    TCAAGACTTCCAGAGACTGATAGAGACCGATGCCG
    AGATCTACATGGGTTTCCATCAGATGTTCGAGCAG
    GTCCCCAAGAAAACTCCGTACGATAAAGACCCCAC
    CAATGAGCAATGGCAAGTAAGAAATTATATGCACA
    TGTTAGATCTGTTCGACCTAATTATAACCGAGGCA
    CCGGATTTCGAACAAAATGATCTTGTTGGATTTCC
    AATAAATGCAATCCTGGATTGGCCCATGGGGACCC
    CCGGTGGGCTTACTGCATTTATTAACCCTAAAGTA
    AATATTATGTTTCATAAAATGTTTGACGTTTGGGC
    AGTATTTCTGTCATCTCCAGCATCATGCTACGTCC
    TAAATACAAGCGATAGCGGTTGGTTCGGTCCCGCT
    GCAACCGCAGCTATACCCAACTTCAAAGAGACCTT
    CATCTGCGACCCAAGTCTGCCATACCTAGGGTACA
    CTAGCTGGGATAATTTCTTCACCAGGCTGTTTAGG
    CCGGGGGTGCGTCCTGTCGAGTTCCCGAACAATGA
    TGCCATTGTTAACAGTGCGTGTGAATCCACGGTTT
    ATAATATAGCTCCAAACATTAAACCACTAGATAAA
    TTTTGGATTAAGGGAGAGCCGTATTCCCTAAATCA
    CATACTTAATAACGACCCGTACGCGAGCCAGTTCG
    TAGGTGGAACCATATCCCAAGCATTCTTATCTGCG
    CTGAACTATCACCGTTGGGCGAGTCCGGTTAACGG
    CAACATTGTCAAGGTCGTCAATGTTCCGGGTACAT
    ACTACGCGGAGTCCCCAGTTACCGGTTTTGGGAAT
    CCAGAAGGGCCAGATCCAGCGGCGCCCAATCTATC
    TCAAGGTTTCATTACTGCTGTGGCTGCGAGAGCCC
    TGATTTTCATAGAGGCCGATAACCCTAACATCGGA
    TTAATGTGTTTTGTGGGGGTTGGCATGGCAGAGGT
    CTCAACATGTGAAGTTACCGTGAGTGTAGGCGATG
    TTGTCAAGAAAGGAGATGAGATTGGAATGTTCCAT
    TTCGGGGGAAGCACTCACTGCTTGATATTTAGGCC
    ACAAACAAAAATTACGTTCAATCCCGACTATCCTG
    TGTCAACCGCCGTACCCTTGAATGCTGCAGTGGCA
    ACCGTCGTATAA
    (Psilocybe cubensis (PSIH gene))
    SEQ ID NO: 4
    ATGATTGCCGTCTTATTCTCTTTTGTCATAGCTGG
    CTGCATCTATTATATAGTATCCCGTCGTGTGCGTC
    GTTCAAGACTTCCGCCCGGACCACCAGGCATCCCT
    ATCCCCTTTATCGGCAATATGTTTGACATGCCCGA
    AGAATCACCCTGGTTGACGTTTCTGCAATGGGGCA
    GAGATTATAATACAGACATTTTGTATGTAGATGCA
    GGCGGAACTGAGATGGTAATATTGAATACCCTTGA
    GACAATCACTGATTTGTTAGAAAAGAGGGGGTCTA
    TATATTCTGGCAGGCTAGAAAGTACCATGGTTAAT
    GAGTTGATGGGGTGGGAGTTTGATCTAGGATTCAT
    CACCTACGGTGATCGTTGGAGAGAGGAGAGAAGGA
    TGTTCGCGAAAGAGTTCAGCGAAAAGGGAATCAAA
    CAATTCAGGCACGCCCAAGTAAAGGCGGCGCATCA
    ACTTGTCCAACAGCTGACAAAAACACCGGATCGTT
    GGGCTCAACACATACGTCATCAGATAGCCGCCATG
    TCTTTAGACATCGGCTATGGCATAGACTTAGCGGA
    GGATGATCCATGGTTAGAAGCAACACACTTAGCTA
    ACGAAGGACTGGCGATAGCTTCCGTCCCAGGAAAA
    TTTTGGGTAGACTCATTTCCGTCTCTGAAATACCT
    ACCAGCCTGGTTTCCTGGAGCTGTCTTCAAACGTA
    AGGCAAAAGTATGGAGGGAGGCAGCAGACCATATG
    GTGGACATGCCATATGAGACTATGAGGAAATTGGC
    GCCACAGGGCTTGACTAGACCATCCTATGCATCTG
    CAAGACTACAGGCCATGGACCTAAACGGTGATTTG
    GAGCACCAAGAGCACGTAATTAAAAACACAGCAGC
    CGAAGTGAACGTCGGAGGGGGAGATACAACCGTCT
    CTGCGATGAGTGCGTTCATACTAGCGATGGTCAAG
    TATCCGGAAGTACAGCGTAAAGTCCAGGCCGAGCT
    AGACGCACTTACTAACAACGGCCAGATTCCCGATT
    ACGACGAGGAAGACGATAGTCTACCTTACTTGACC
    GCATGTATTAAAGAGTTATTTAGATGGAATCAAAT
    TGCGCCCCTAGCGATTCCTCACAAGTTAATGAAAG
    ACGATGTATATAGGGGTTATCTAATACCTAAGAAT
    ACGCTAGTTTTTGCAAACACATGGGCGGTCCTGAA
    CGACCCTGAAGTCTACCCAGACCCTAGCGTATTTA
    GGCCGGAGCGTTATTTAGGACCCGACGGTAAGCCC
    GATAATACTGTCAGGGACCCCAGGAAGGCTGCGTT
    CGGGTATGGGAGGAGGAACTGTCCAGGAATACACT
    TAGCCCAATCAACCGTCTGGATAGCCGGAGCGACC
    TTACTTAGTGCGTTTAATATCGAGAGGCCAGTTGA
    CCAGAATGGGAAACCCATCGATATTCCAGCAGACT
    TCACAACCGGGTTTTTCAGGCATCCTGTTCCTTTT
    CAGTGCCGTTTCGTGCCTAGGACTGAACAGGTCTC
    CCAATCAGTCAGTGGGCCGTAA
    (Psilocybe cyanescens (PSIH gene))
    SEQ ID NO: 5
    ATGGCGCCTTTGACAACCATGATTCCGATCGTTCT
    ATCTCTTCTAATAGCGGGGTGTATATATTATATCA
    ACGCAAGGAGAATTAAAAGGTCCAGGTTGCCACCA
    GGACCGCCGGGTATTCCTATTCCATTCATCGGGAA
    CATGTTCGACATGCCAAGCGAAAGTCCCTGGCTAA
    TCTTCCTACAATGGGGACAAGAGTACCAGACCGAT
    ATAATTTACGTTGACGCGGGAGGAACTGATATGAT
    AATACTTAATTCCCTAGAGGCAATTACAGATCTGT
    TAGAGAAAAGGGGCTCATTGTATAGCGGGAGGTTG
    GAATCCACGATGGTAAACGAGCTAATGGGTTGGGA
    GTTTGATTTCGGTTTCATACCTTACGGTGAAAGAT
    GGAGGGAAGAACGTCGTATGTTCGCCAAAGAGTTT
    TCTGAGAAGAACATAAGGCAGTTTAGACACGCCCA
    AGTAAAGGCTGCCAATCAGCTAGTGCGTCAACTAA
    CCGATAAACCGGACAGGTGGTCACACCACATAAGG
    CATCAAATCGCGTCCATGGCCCTGGACATCGGTTA
    CGGAATCGATCTTGCTGAAGACGATCCGTGGATCG
    CAGCTTCCGAACTGGCGAATGAAGGCTTGGCTGTA
    GCCTCAGTGCCAGGATCTTTTTGGGTAGATACGTT
    CCCGTTTCTTAAATATTTGCCAAGTTGGTTACCTG
    GCGCGGAGTTCAAAAGAAACGCAAAGATGTGGAAG
    GAAGGAGCAGATCATATGGTCAATATGCCTTACGA
    AACGATGAAAAAGCTAAGCGCACAAGGACTGACTA
    GACCATCATATGCAAGTGCGAGGCTACAGGCTATG
    GACCCGAACGGGGATCTTGAACATCAAGAAAGAGT
    GATCAAAAATACGGCCACGCAGGTAAATGTTGGTG
    GTGGGGATACTACAGTCGGGGCAGTAAGTGCGTTT
    ATCCTTGCGATGGTAAAATACCCGGAAGTTCAAAG
    GAAAGTACAAGCCGAGCTGGACGAGTTCACGAGCA
    AGGGGAGGATACCGGATTACGATGAAGATAACGAT
    TCTCTTCCCTATCTATCGGCTTGCTTCAAAGAGCT
    GTTCAGGTGGGGCCAGATTGCGCCTTTGGCGATTG
    CTCATAGGCTGATAAAGGACGATGTCTATAGGGAA
    TATACTATCCCAAAGAATGCTCTGGTCTTTGCGAA
    CAATTGGTATGGGCGTACTGTATTGAATGACCCTT
    CTGAGTATCCCAATCCTTCAGAATTTAGACCTGAA
    AGGTACTTGGGGCCCGATGGTAAGCCAGATGACAC
    CGTCAGGGACCCAAGAAAGGCAGCGTTTGGGTACG
    GACGTAGAGTGTGTCCAGGGATACACCTGGCGCAG
    AGCACGGTCTGGATTGCTGGTGTCGCGTTGGTATC
    TGCCTTCAACATTGAGCTGCCCGTGGACAAAGACG
    GGAAATGTATAGATATTCCGGCGGCCTTCACGACG
    GGATTCTTTAGATAA
    (Gymnopilusjunonius (PSIH gene))
    SEQ ID NO: 6
    ATGATGTCCGAGATGAATGGGATGGATAAATTGGC
    GCTATTGACGACGTTATTAGCTGCCGGTTTTCTAT
    ACTTCAAGAATAAGCGTCGTTCCGCGTTGCCGTTC
    CCGCCAGGGCCGAAAAAGCATCCCCTTTTAGGTAA
    CTTGCTGGACCTTCCGAAGAAGCTGGAGTGGGAGA
    CGTACAGAAGATGGGGAAAAGAATACAATTCAGAT
    GTAATACATGTTAGCGCGGGGAGTGTAAACTTAAT
    TATCGTTAATTCCTTTGAAGCTGCGACAGACCTGT
    TTGATAAGAGATCAGCCAATTATTCAAGTAGGCCA
    CAATTCACGATGGTGAGAGAACTGATGGGATGGAA
    TTGGTTGATGTCTGCATTAATATACGGTGACAAGT
    GGAGAGAGCAACGTAGGTTGTTTCAGAAACATTTC
    AGTACAACGAATGCCGAACTTTACCAAAATACACA
    ATTAGAATATGTTCGTAAAGCCCTGCAGCATCTGC
    TAGAAGAGCCTTCAGATTTTATGGGAATAACACGT
    CACATGGCTGGGGGCGTCAGCATGTCCCTGGCATA
    TGGCTTAAACATTCAGAAGAAAAACGACCCTTTTG
    TTGACCTTGCACAAAGGGCAGTGCACAGCATAACA
    GAGGCCTCAGTTCCTGGGACATTTTGGGTAGACGT
    AATGCCTTGGCTAAAGTATATTCCAGAATGGGTGC
    CGGGTGCTGGCTTTCAGAAGAAGGCTAGAGTGTGG
    AGGAAATTACAGCAAGATTTTCGTCAGGTCCCATA
    TCAGGCAGCTCTGAAAGACATGGCTTCAGGGAAAG
    CTAAACCATCATTTGCAAGTGAGTGTTTGGAGACG
    ATAGACGACAATGAGGATGCACAAAGGCAAAGGGA
    GGTGATAAAAGACACAGCTGCCATTGTATTCGCAG
    CCGGTGCGGATACAAGCCTTAGTGGAATCCATACA
    TTATTCGCCGCAATGTTGTGTTACCCAGAGGTCCA
    GAAGAAAGCACAAGAAGAACTGGATCGTGTCTTGG
    GTGGGAGACGTCTACCGGAATTTACCGATGAGCCC
    AACATGCCCTACATCTCTGCGTTAGTGAAGGAAAT
    ATTGAGGTGGAAACCGGCTACTCCGATTGGCGTAC
    CCCACTTAGCCAGCGAGGATGACGTTTACAACGGA
    TATTACATACCAAAACGTGCGGTTGTCATAGGCAA
    CAGCTGGGCTATGCTTCATGATGAGGAAACTTATC
    CGGACCCAAGCACCTTTAACCCTGACAGATTTTTG
    ACCACAAATAAAAGCACTGGAAAATTGGAATTAGA
    TCCCACAGTGAGAGATCCCGCTTTAATGGCCTTCG
    GATTTGGTAGACGTATGTGTCCAGGACGTGATGTA
    GCTCTTTCTGTCATATGGCTGACTATCGCAAGCGT
    TTTAGCAACGTTTAATATTACCAAGGCGATAGACG
    AAAACGGGAAGGAACTGGAACCGGATGTACAGTAC
    TGGAGCGGTCTAATCGTCCACCCGCTGCCATTCAA
    ATGTACGATCAAGCCAAGATCAAAGGCAGCGGAAG
    AACTTGTGAAATCTGGCGCAGACGCCTATTAA
    (Psilocybecubensis (PSIK gene))
    SEQ ID NO: 7
    ATGGCATTCGACTTGAAAACTGAAGACGGGCTAAT
    AACTTACCTAACGAAACACCTTTCTTTGGATGTGG
    ATACATCAGGTGTGAAAAGGTTAAGCGGTGGCTTC
    GTTAACGTGACCTGGAGAATAAAACTAAACGCACC
    CTATCAGGGTCACACATCAATAATTCTAAAGCACG
    CACAGCCGCATATGTCAACCGACGAAGACTTCAAA
    ATTGGCGTGGAGCGTTCCGTCTATGAGTACCAGGC
    TATCAAACTTATGATGGCCAATAGGGAGGTGCTAG
    GGGGTGTTGACGGGATCGTGTCTGTGCCAGAGGGG
    TTGAACTACGACCTTGAAAATAATGCATTGATCAT
    GCAGGACGTAGGTAAGATGAAGACCCTATTAGACT
    ACGTAACGGCAAAACCCCCGCTTGCGACTGATATA
    GCACGTTTGGTAGGTACAGAGATTGGGGGTTTCGT
    GGCTAGACTGCATAACATAGGGAGGGAGAGGAGAG
    ACGACCCGGAGTTCAAGTTTTTCTCTGGAAATATA
    GTCGGCAGGACAACAAGCGATCAACTATACCAAAC
    AATTATCCCTAACGCAGCTAAGTACGGGGTAGATG
    ACCCTCTACTGCCTACCGTTGTAAAAGATCTGGTC
    GATGATGTCATGCACAGTGAGGAGACTCTTGTAAT
    GGCGGATTTATGGAGCGGCAATATACTTCTACAGT
    TGGAGGAGGGGAATCCTTCAAAGTTACAGAAAATC
    TACATTTTAGATTGGGAATTGTGTAAATACGGCCC
    AGCTTCACTAGACCTTGGGTATTTCTTGGGTGATT
    GCTACCTGATTTCTCGTTTCCAAGATGAGCAGGTC
    GGCACAACTATGAGACAAGCCTACTTACAAAGCTA
    CGCTCGTACCTCTAAACATTCCATAAACTACGCCA
    AGGTCACTGCGGGAATTGCAGCACATATAGTGATG
    TGGACAGACTTTATGCAGTGGGGGAGTGAGGAAGA
    GAGAATTAACTTCGTCAAGAAAGGCGTGGCCGCCT
    TCCATGACGCAAGAGGGAACAATGATAATGGTGAA
    ATCACCTCTACTCTGTTGAAGGAGAGTTCAACTGC
    CTAA
    (Psilocybecyanescens (PSIK gene))
    SEQ ID NO: 8
    ATGACTTTCGATCTAAAAACGGAGGAGGGCTTATT
    ATCTTATCTTACCAAGCATTTAAGTTTAGACGTAG
    CACCGAATGGTGTCAAAAGATTATCTGGTGGATTC
    GTCAATGTGACTTGGAGGGTAGGGTTAAATGCACC
    GTACCATGGGCACACGTCTATAATCCTTAAACACG
    CTCAACCACATTTAAGCTCCGATATTGACTTCAAA
    ATAGGGGTGGAAAGAAGTGCGTATGAGTACCAGGC
    TTTGAAGATTGTCTCTGCCAACAGCAGCCTACTTG
    GTTCTTCTGATATCCGTGTCTCAGTTCCAGAAGGT
    TTGCACTATGATGTTGTGAATAACGCCCTAATCAT
    GCAGGACGTGGGTACAATGAAGACCTTGCTGGACT
    ATGTTACAGCGAAACCCCCTATATCTGCTGAAATT
    GCCAGCCTAGTAGGTAGTCAGATTGGCGCTTTCAT
    AGCAAGATTACACAATTTGGGCAGAGAAAATAAAG
    ATAAGGACGACTTTAAATTTTTCTCCGGAAATATA
    GTTGGGAGGACGACGGCAGACCAACTGTATCAGAC
    CATAATTCCTAATGCGGCAAAATATGGAATCGATG
    ACCCAATTCTTCCAATAGTTGTCAAAGAACTTGTT
    GAAGAAGTCATGAACTCAGAGGAAACCCTGATTAT
    GGCGGACCTATGGAGCGGTAATATCTTGCTACAGT
    TCGACGAGAACAGTACGGAACTAACCCGTATTTGG
    CTGGTAGACTGGGAGCTATGCAAGTACGGGCCGCC
    GTCACTGGATATGGGTTACTTCTTGGGCGACTGCT
    TTTTGGTAGCTAGATTCCAAGACCAACTTGTAGGC
    ACATCTATGAGACAAGCATACCTTAAAAGCTACGC
    ACGTAACGTAAAAGAGCCGATCAACTATGCTAAGG
    CCACAGCAGGCATCGGCGCTCATTTGGTAATGTGG
    ACTGACTTCATGAAGTGGGGTAACGATGAAGAAAG
    GGAGGAGTTCGTGAAAAAGGGGGTCGAAGCATTCC
    ACGAGGCCAACGAAGACAATAGGAACGGAGAGATA
    ACGAGCATATTGGTGAAAGAGGCATCACGTACGTA
    A
    (Psilocybecubensis (PSIM gene))
    SEQ ID NO: 9
    ATGCACATCAGAAACCCCTATAGAACCCCCATAGA
    TTACCAGGCGCTGAGTGAGGCCTTTCCACCATTGA
    AGCCCTTTGTATCCGTAAACGCTGATGGTACGAGT
    TCCGTAGATCTAACGATCCCGGAGGCGCAACGTGC
    GTTCACTGCCGCATTGTTACATAGAGATTTCGGGC
    TAACCATGACTATACCGGAAGATAGACTGTGCCCT
    ACTGTCCCTAACAGGTTAAATTATGTACTGTGGAT
    TGAAGATATTTTCAACTACACGAATAAGACCCTGG
    GGCTGAGCGATGACAGACCGATAAAGGGGGTGGAT
    ATTGGCACAGGCGCCAGCGCAATATACCCTATGCT
    TGCTTGCGCCAGGTTTAAGGCATGGTCCATGGTAG
    GGACAGAGGTAGAACGTAAATGTATTGATACGGCT
    AGACTAAATGTCGTCGCCAATAATCTACAGGATAG
    ATTGAGTATATTAGAGACATCCATCGACGGTCCCA
    TTCTTGTTCCAATCTTCGAGGCCACAGAAGAATAT
    GAGTATGAGTTCACCATGTGTAATCCGCCATTCTA
    CGATGGTGCGGCCGACATGCAGACCTCTGACGCGG
    CCAAAGGATTCGGCTTTGGAGTGGGGGCCCCTCAC
    TCTGGAACAGTTATCGAAATGTCCACTGAAGGAGG
    GGAGTCCGCATTCGTAGCCCAGATGGTGAGAGAGA
    GCTTGAAACTGCGTACCAGATGCAGATGGTATACG
    TCTAATCTTGGGAAATTAAAAAGCCTAAAGGAGAT
    TGTGGGTCTTTTAAAAGAGCTGGAGATTTCCAACT
    ACGCCATAAACGAGTACGTCCAAGGGTCTACCAGA
    AGATACGCCGTCGCGTGGTCTTTTACTGACATTCA
    GCTTCCAGAGGAGCTATCTCGTCCCAGTAACCCGG
    AATTGTCCTCCTTGTTTTAA
    (Psilocybecyanescens (PSIM gene))
    SEQ ID NO: 10
    ATGCATATCAGGAATCCGTACCGTGACGGCGTGGA
    CTACCAGGCATTAGCCGAGGCTTTCCCGGCGCTAA
    AGCCACACGTCACTGTCAATTCAGACAATACAACT
    TCTATAGATTTCGCGGTACCCGAGGCCCAGAGACT
    TTACACCGCAGCATTACTTCATAGGGACTTTGGTT
    TAACCATAACCTTACCCGAGGATAGACTATGTCCT
    ACGGTCCCGAATAGATTGAACTATGTGTTGTGGGT
    GGAAGATATACTGAAGGTTACGTCAGACGCATTGG
    GATTACCGGATAATAGACAAGTGAAAGGTATTGAT
    ATTGGAACAGGAGCAAGCGCAATTTATCCCATGTT
    AGCTTGTTCCAGGTTTAAGACTTGGTCCATGGTAG
    CTACAGAGGTGGATCAAAAATGCATAGATACCGCA
    AGGCTAAACGTAATAGCTAATAACCTTCAGGAGAG
    ATTGGCAATCATAGCCACTTCCGTGGACGGGCCTA
    TTCTTGTTCCTCTGTTGCAGGCTAATTCCGACTTT
    GAATATGACTTCACCATGTGCAATCCGCCCTTTTA
    CGACGGCGCCTCTGATATGCAGACAAGTGATGCCG
    CTAAAGGCTTTGGCTTCGGAGTAAACGCACCTCAC
    ACTGGGACAGTACTTGAAATGGCGACAGAAGGAGG
    GGAAAGTGCGTTCGTTGCCCAAATGGTTCGTGAGT
    CCTTGAACCTGCAGACTAGATGCAGGTGGTTCACA
    TCTAATTTGGGTAAACTAAAATCACTGTACGAGAT
    TGTGGGTCTATTAAGAGAACACCAGATTTCTAACT
    ACGCCATAAATGAGTATGTACAAGGCGCAACTCGT
    AGGTATGCAATTGCGTGGAGTTTCATAGATGTAAG
    ACTGCCCGACCATTTGTCCAGACCATCTAATCCCG
    ATCTATCCAGTTTGTTTTAA
    (Panaeoluscyanescens (PSIM gene))
    SEQ ID NO: 11
    ATGCATAACCGTAACCCGTATAGGGACGTGATTGA
    TTACCAAGCACTTGCGGAAGCCTACCCGCCCCTAA
    AACCCCACGTCACGGTGAACGCGGATAACACGGCA
    TCCATAGATCTTACGATCCCCGAGGTCCAGAGGCA
    ATACACAGCAGCTCTTTTACATCGTGATTTCGGAT
    TAACTATCACACTACCAGAAGATAGGCTGTGCCCG
    ACAGTACCGAACCGTTTAAACTATGTATTGTGGAT
    AGAGGATATATTTCAGTGTACGAATAAGGCTCTGG
    GATTGTCAGATGACAGACCCGTTAAGGGGGTAGAT
    ATAGGGACCGGCGCCTCCGCCATCTATCCAATGCT
    TGCTTGCGCGAGGTTTAAGCAGTGGTCCATGATTG
    CCACAGAAGTGGAGCGTAAGTGCATAGATACAGCG
    AGATTGAATGTCCTGGCGAATAACTTACAGGACCG
    TTTGTCAATTCTTGAGGTTTCAGTAGACGGCCCGA
    TTTTGGTACCCATCTTTGATACCTTCGAGCGTGCG
    ACAAGCGATTACGAATTTGAGTTCACGATGTGTAA
    CCCTCCATTTTACGACGGGGCCGCGGATATGCAAA
    CATCAGATGCAGCTAAGGGTTTCGGTTTTGGAGTT
    AACGCTCCACACTCCGGTACCGTGATAGAGATGGC
    TACTGAAGGAGGTGAGGCTGCTTTTGTGGCGCAAA
    TGGTCCGTGAGAGCATGAAGTTACAGACAAGGTGT
    CGTTGGTTTACAAGCAACTTAGGCAAGCTAAAATC
    ACTGCATGAAATTGTTGCTTTGTTGAGAGAATCCC
    AGATCACAAACTATGCCATAAATGAGTACGTTCAG
    GGGACGACGAGAAGGTACGCTCTTGCTTGGTCCTT
    CACAGACATAAAACTTACTGAGGAACTTTACAGGC
    CCTCCAATCCAGAATTAGGACCTCTTTGCAGCACA
    TTTGTCTAA
    (Gymnopilusdilepis (PSIM gene))
    SEQ ID NO: 12
    ATGCACATTAGAAACCCTTACTTAACACCTCCGGA
    CTACGAGGCCCTTGCGGAGGCCTTCCCCGCACTAA
    AGCCTTATGTTACAGTTAACCCCGATAAGACTACT
    ACAATTGACTTTGCCATACCGGAGGCTCAGAGATT
    ATACACGGCTGCTCTACTTTACAGGGACTTTGGAC
    TGACAATAACATTGCCGCCGGATAGGTTATGCCCA
    ACCGTGCCCAATAGGCTTAATTATGTTTTGTGGAT
    TCAGGACATTCTGCAGATTACCTCCGCTGCCTTGG
    GCTTGCCAGAGGCTAGACAAGTAAAGGGAGTAGAC
    ATAGGTACCGGAGCGGCAGCGATATACCCTATTCT
    TGGTTGCAGCCTTGCAAAGAATTGGTCTATGGTGG
    GGACAGAGGTCGAACAAAAATGTATCGACATAGCG
    CGTCAAAACGTGATTTCAAATGGATTGCAGGATAG
    GATAACCATAACTGCTAATACCATAGACGCTCCCA
    TTCTGCTGCCCTTATTTGAAGGAGACAGTAACTTC
    GAATGGGAGTTCACCATGTGTAACCCGCCATTTTA
    CGACGGCGCTGCGGACATGGAGACAAGCCAGGACG
    CTAAAGGCTTCGGGTTCGGCGTCAACGCCCCGCAT
    ACAGGAACAGTGGTGGAAATGGCCACGGACGGTGG
    TGAGGCTGCATTCGTCAGCCAAATGGTGAGAGAGT
    CCTTGCACCTAAAGACACGTTGTAGATGGTTCACG
    TCCAATCTAGGTAAATTGAAGAGTCTACATGAAAT
    TGTGGGATTGTTGCGTGAACACCAAATTACCAACT
    ACGCGATAAATGAATATGTTCAGGGAACGACACGT
    AGATACGCGATTGCATGGTCATTTACTGACCTACG
    TCTATCAGACCACCTGCCACGTCCTCCGAACCCCG
    ATCTATCAGCCCTATTTTAA
    (Gymnopilusjunonius (PSIM gene))
    SEQ ID NO: 13
    ATGCACTCTCGTAACCCTTATAGATCCCCTCCTGA
    TTTCGCGGCATTAAGTGCGGCTTATCCTCCGCTGT
    CACCATACATAACTACCGATCTAAGCAGCGGTCGT
    AAAACAATTGACTTTAGAAATGAGGAAGCGCAACG
    TCGTCTAACTGAGGCTATCATGTTGCGTGACTTCG
    GCGTTGTGTTAAACATACCATCTAACAGGCTGTGC
    CCGCCTGTGCCGAATCGTATGAACTATGTACTTTG
    GATACAAGATATAGTTTACGCGCACCAGACAATAC
    TGGGAGTGAGTTCTCGTCGTATCAGAGGTCTTGAT
    ATTGGTACTGGTGCTACCGCTATATATCCTATACT
    GGCATGCAAGAAAGAGCAGAGCTGGGAGATGGTTG
    CAACTGAATTGGACGACTACTCCTATGAGTGTGCA
    TGTGATAACGTGTCATCCAACAATATGCAGACTTC
    CATTAAAGTAAAGAAGGCTTCGGTAGATGGGCCCA
    TCCTGTTCCCAGTGGAAAACCAAAATTTCGACTTT
    AGCATGTGCAACCCGCCTTTCTACGGCTCTAAGGA
    GGAGGTGGCGCAATCCGCAGAGTCAAAAGAACTGC
    CGCCCAATGCTGTTTGCACGGGTGCAGAGATCGAG
    ATGATATTTAGTCAAGGAGGAGAAGAGGGTTTCGT
    AGGTAGAATGGTAGAGGAATCAGAGAGGTTGCAAA
    CGAGATGCAAATGGTACACTTCAATGCTTGGTAAG
    ATGTCTAGTGTAAGCACTATAGTTCAGGCTCTGCG
    TGCGAGATCAATTATGAATTATGCTTTGACAGAAT
    TTGTACAAGGACAAACCCGTAGGTGGGCGATAGCT
    TGGTCTTTCTCCGACACTCACTTACCGGATGCCGT
    CAGTAGAATCTCTAGTTAA
    (Psilocybecubensis (PSID gene))
    SEQ ID NO: 14
    MQVIPACNSAAIRSLCPTPESFRNMGWLSVSDAVY
    SEFIGELATRASNRNYSNEFGLMQPIQEFKAFIES
    DPVVHQEFIDMFEGIQDSPRNYQELCNMFNDIFRK
    APVYGDLGPPVYMIMAKLMNTRAGFSAFTRQRLNL
    HFKKLFDTWGLFLSSKDSRNVLVADQFDDRHCGWL
    NERALSAMVKHYNGRAFDEVFLCDKNAPYYGFNSY
    DDFFNRRFRNRDIDRPVVGGVNNTTLISAACESLS
    YNVSYDVQSLDTLVFKGETYSLKHLLNNDPFTPQF
    EHGSILQGFLNVTAYHRWHAPVNGTIVKIINVPGT
    YFAQAPSTIGDPIPDNDYDPPPYLKSLVYFSNIAA
    RQIMFIEADNKEIGLIFLVFIGMTEISTCEATVSE
    GQHVNRGDDLGMFHFGGSSFALGLRKDCRAEIVEK
    FTEPGTVIRINEVVAALKA
    (Psilocybecyanescens (PSID gene))
    SEQ ID NO: 15
    MQVLPACQSSALKTLCPSPEAFRKLGWLPTSDEVY
    NEFIDDLTGRTCNEKYSSQVTLLKPIQDFKTFIEN
    DPIVYQEFISMFEGIEQSPTNYHELCNMFNDIFRK
    APLYGDLGPPVYMIMARIMNTQAGFSAFTKESLNF
    HFKKLFDTWGLFLSSKNSRNVLVADQFDDKHYGWF
    SERAKTAMMINYPGRTFEKVFICDEHVPYHGFTSY
    DDFFNRRFRDKDTDRPVVGGVTDTTLIGAACESLS
    YNVSHNVQSLDTLVIKGEAYSLKHLLHNDPFTPQF
    EHGSIIQGFLNVTAYHRWHSPVNGTIVKIVNVPGT
    YFAQAPYTIGSPIPDNDRDPPPYLKSLVYFSNIAA
    RQIMFIEADNKDIGLIFLVFIGMTEISTCEATVCE
    GQHVNRGDDLGMFHFGGSSFALGLRKDSKAKILEK
    FAKPGTVIRINELVASVRK
    (Gymnopilusjunonius (PSID gene))
    SEQ ID NO: 16
    MSSPRIVLHRVGGWLPKDQNVLEAWLSKKIAKAKT
    RNRAPKDWAPVIQDFQRLIETDAEIYMGFHQMFEQ
    VPKKTPYDKDPTNEQWQVRNYMHMLDLFDLIITEA
    PDFEQNDLVGFPINAILDWPMGTPGGLTAFINPKV
    NIMFHKMFDVWAVFLSSPASCYVLNTSDSGWFGPA
    ATAAIPNFKETFICDPSLPYLGYTSWDNFFTRLFR
    PGVRPVEFPNNDAIVNSACESTVYNIAPNIKPLDK
    FWIKGEPYSLNHILNNDPYASQFVGGTISQAFLSA
    LNYHRWASPVNGNIVKVVNVPGTYYAESPVTGFGN
    PEGPDPAAPNLSQGFITAVAARALIFIEADNPNIG
    LMCFVGVGMAEVSTCEVTVSVGDVVKKGDEIGMFH
    FGGSTHCLIFRPQTKITFNPDYPVSTAVPLNAAVA
    TVV
    (Psilocybecubensis (PSIH gene))
    SEQ ID NO: 17
    MIAVLFSFVIAGCIYYIVSRRVRRSRLPPGPPGIP
    IPFIGNMFDMPEESPWLTFLQWGRDYNTDILYVDA
    GGTEMVILNTLETITDLLEKRGSIYSGRLESTMVN
    ELMGWEFDLGFITYGDRWREERRMFAKEFSEKGIK
    QFRHAQVKAAHQLVQQLTKTPDRWAQHIRHQIAAM
    SLDIGYGIDLAEDDPWLEATHLANEGLAIASVPGK
    FWVDSFPSLKYLPAWFPGAVFKRKAKVWREAADHM
    VDMPYETMRKLAPQGLTRPSYASARLQAMDLNGDL
    EHQEHVnCNTAAEVNVGGGDTTVSAMSAFILAMVK
    YPEVQRKVQAELDALTNNGQIPDYDEEDDSLPYLT
    ACIKELFRWNQIAPLAIPHKLMKDDVYRGYLIPKN
    TLVFANTWAVLNDPEVYPDPSVFRPERYLGPDGKP
    DNTVRDPRKAAFGYGRRNCPGIHLAQSTVWIAGAT
    LLSAFNIERPVDQNGKPIDIPADFTTGFFRHPVPF
    QCRFVPRTEQVSQSVSGP
    (Psilocybecyanescens (PSIH gene))
    SEQ ID NO: 18
    MAPLTTMIPIVLSLLIAGCIYYINARRIKRSRLPP
    GPPGIPIPFIGNMFDMPSESPWLIFLQWGQEYQTD
    IIYVDAGGTDMIILNSLEAITDLLEKRGSLYSGRL
    ESTMVNELMGWEFDFGFIPYGERWREERRMFAKEF
    SEKNIRQFRHAQVKAANQLVRQLTDKPDRWSHHIR
    HQIASMALDIGYGIDLAEDDPWIAASELANEGLAV
    ASVPGSFWVDTFPFLKYLPSWLPGAEFKRNAKMWK
    EGADHMVNMPYETMKKLSAQGLTRPSYASARLQAM
    DPNGDLEHQERVIKNTATQVNVGGGDTTVGAVSAF
    ILAMVKYPEVQRKVQAELDEFTSKGRIPDYDEDND
    SLPYLSACFKELFRWGQIAPLAIAHRLIKDDVYRE
    YTIPKNALVFANNWYGRTVLNDPSEYPNPSEFRPE
    RYLGPDGKPDDTVRDPRKAAFGYGRRVCPGIHLAQ
    STVWIAGVALVSAFNIELPVDKDGKCIDIPAAFTT
    GFFR
    (Gymnopilusjunonius (PSIH gene))
    SEQ ID NO: 19
    MMSEMNGMDKLALLTTLLAAGFLYFKNKRRSALPF
    PPGPKKHPLLGNLLDLPKKLEWETYRRWGKEYNSD
    VIHVSAGSVNLIIVNSFEAATDLFDKRSANYSSRP
    QFTMVRELMGWNWLMSALIYGDKWREQRRLFQKHF
    STTNAELYQNTQLEYVRKALQHLLEEPSDFMGITR
    HMAGGVSMSLAYGLNIQKKNDPFVDLAQRAVHSIT
    EASVPGTFWVDVMPWLKYIPEWVPGAGFQKKARVW
    RKLQQDFRQVPYQAALKDMASGKAKPSFASECLET
    IDDNEDAQRQREVIKDTAAIVFAAGADTSLSGIHT
    LFAAMLCYPEVQKKAQEELDRVLGGRRLPEFTDEP
    NMPYISALVKEILRWKPATPIGVPHLASEDDVYNG
    YYIPKRAVVIGNSWAMLHDEETYPDPSTFNPDRFL
    TTNKSTGKLELDPTVRDPALMAFGFGRRMCPGRDV
    ALSVIWLTIASVLATFNITKAIDENGKELEPDVQY
    WSGLIVHPLPFKCTIKPRSKAAEELVKSGADAY
    (Psilocybecubensis (PSIK gene))
    SEQ ID NO: 20
    MAFDLKTEDGLITYLTKHLSLDVDTSGVKRLSGGF
    VNVTWRIKLNAPYQGHTSIILKHAQPHMSTDEDFK
    IGVERSVYEYQAIKLMMANREVLGGVDGIVSVPEG
    LNYDLENNALIMQDVGKMKTLLDYVTAKPPLATDI
    ARLVGTEIGGFVARLHNIGRERRDDPEFKFFSGNI
    VGRTTSDQLYQTIIPNAAKYGVDDPLLPTVVKDLV
    DDVMHSEETLVMADLWSGNILLQLEEGNPSKLQKI
    YILDWELCKYGPASLDLGYFLGDCYLISRFQDEQV
    GTTMRQAYLQSYARTSKHSINYAKVTAGIAAHIVM
    WTDFMQWGSEEERINFVKKGVAAFHD ARGNNDNG
    EITSTLLKESSTA
    (Psilocybecyanescens (PSIK gene))
    SEQ ID NO: 21
    MTFDLKTEEGLLSYLTKHLSLDVAPNGVKRLSGGF
    VNVTWRVGLNAPYHGHTSIILKHAQPHLSSDIDFK
    IGVERSAYEYQALKIVSANSSLLGSSDIRVSVPEG
    LHYDVVNNALIMQDVGTMKTLLDYVTAKPPISAEI
    ASLVGSQIGAFIARLHNLGRENKDKDDFKFFSGNI
    VGRTTADQLYQTIIPNAAKYGIDDPILPIVVKELV
    EEVMNSEETLIMADLWSGNILLQFDENSTELTRIW
    LVDWELCKYGPPSLDMGYFLGDCFLVARFQDQLVG
    TSMRQAYLKSYARNVKEPINYAKATAGIGAHLVMW
    TDFMKWGNDEEREEFVKKGVEAFHEANEDNRNGEI
    TSILVKEASRT
    (Psilocybecyanescens (PSIM gene))
    SEQ ID NO: 22
    MHIRNPYRDGVDYQALAEAFPALKPHVTVNSDNTT
    SIDFAVPEAQRLYTAALLHRDFGLTITLPEDRLCP
    TVPNRLNYVLWVEDILKVTSDALGLPDNRQVKGID
    IGTGASAIYPMLACSRFKTWSMVATEVDQKCIDTA
    RLNVIANNLQERLAIIATSVDGPILVPLLQANSDF
    EYDFTMCNPPFYDGASDMQTSDAAKGFGFGVNAPH
    TGTVLEMATEGGESAFVAQMVRESLNLQTRCRWFT
    SNLGKLKSLYEIVGLLREHQISNYAINEYVQGATR
    RYAIAWSFIDVRLPDHLSRPSNPDLSSLF
    (Psilocybecubensis (PSIM gene))
    SEQ ID NO: 23
    MHIRNPYRTPIDYQALSEAFPPLKPFVSVNADGTS
    SVDLTIPEAQRAFTAALLHRDFGLTMTIPEDRLCP
    TVPNRLNYVLWIEDIFNYTNKTLGLSDDRPIKGVD
    IGTGASAIYPMLACARFKAWSMVGTEVERKCIDTA
    RLNVVANNLQDRLSILETSIDGPILVPIFEATEEY
    EYEFTMCNPPFYDGAADMQTSDAAKGFGFGVGAPH
    SGTVIEMSTEGGESAFVAQMVRESLKLRTRCRWYT
    SNLGKLKSLKEIVGLLKELEISNYAINEYVQGSTR
    RYAVAWSFTDIQLPEELSRPSNPELSSLF
    (Panaeoluscyanescens (PSIM gene))
    SEQ ID NO: 24
    MHNRNPYRDVIDYQALAEAYPPLKPHVTVNADNTA
    SIDLTIPEVQRQYTAALLHRDFGLTITLPEDRLCP
    TVPNRLNYVLWIEDIFQCTNKALGLSDDRPVKGVD
    IGTGASAIYPMLACARFKQWSMIATEVERKCIDTA
    RLNVLANNLQDRLSILEVSVDGPILVPIFDTFERA
    TSDYEFEFTMCNPPFYDGAADMQTSDAAKGFGFGV
    NAPHSGTVIEMATEGGEAAFVAQMVRESMKLQTRC
    RWFTSNLGKLKSLHEIVALLRESQITNYAINEYVQ
    GTTRRYALAWSFTDIKLTEELYRPSNPELGPLCST
    FV
    (Gymnopilusjunonius (PSIM gene))
    SEQ ID NO: 25
    MHSRNPYRSPPDFAALSAAYPPLSPYITTDLSSGR
    KTIDFRNEEAQRRLTEAIMLRDFGVVLNIPSNRLC
    PPVPNRMNYVLWIQDIVYAHQTILGVSSRRIRGLD
    IGTGATAIYPILACKKEQSWEMVATELDDYSYECA
    CDNVSSNNMQTSIKVKKASVDGPILFPVENQNFDF
    SMCNPPFYGSKEEVAQSAESKELPPNAVCTGAEIE
    MIFSQGGEEGFVGRMVEESERLQTRCKWYTSMLGK
    MSSVSTIVQALRARSIMNYALTEFVQGQTRRWAIA
    WSFSDTHLPDAVSRISS
    (Gymnopilusdilepis (PSIM gene))
    SEQ ID NO: 26
    MHIRNPYLTPPDYEALAEAFPALKPYVTVNPDKTT
    TIDFAIPEAQRLYTAALLYRDFGLTITLPPDRLCP
    TVPNRLNYVLWIQDILQITSAALGLPEARQVKGVD
    IGTGAAAIYPILGCSLAKNWSMVGTEVEQKCIDIA
    RQNVISNGLQDRITITANTIDAPILLPLFEGDSNF
    EWEFTMCNPPFYDGAADMETSQDAKGFGFGVNAPH
    TGTVVEMATDGGEAAFVSQMVRESLHLKTRCRWFT
    SNLGKLKSLHEIVGLLREHQITNYAINEYVQGTTR
    RYAIAWSFTDLRLSDHLPRPPNPDLSALF
    (Saccharmycescerevisiae (ARO1 gene))
    SEQ ID NO: 27
    ATGGTTCAACTAGCCAAGGTTCCAATACTAGGAAA
    CGATATAATACACGTTGGATATAATATACACGATC
    ATCTTGTAGAGACAATTATTAAACACTGTCCTTCT
    TCTACTTACGTCATCTGTAACGATACTAACCTTAG
    CAAGGTACCTTATTACCAGCAACTGGTTCTGGAGT
    TCAAAGCAAGTCTTCCCGAAGGCTCCAGACTACTA
    ACCTACGTGGTCAAACCGGGCGAGACGTCTAAGAG
    TAGGGAGACGAAGGCGCAGTTAGAGGATTATCTTT
    TAGTAGAAGGGTGCACTCGTGATACGGTCATGGTA
    GCCATCGGCGGAGGTGTCATCGGTGACATGATCGG
    TTTCGTAGCCTCCACGTTCATGAGAGGTGTGAGGG
    TAGTACAGGTTCCGACGTCTCTTTTAGCAATGGTA
    GACTCATCCATAGGCGGTAAAACGGCGATCGATAC
    TCCGCTAGGAAAGAACTTCATTGGAGCCTTTTGGC
    AGCCAAAATTTGTTCTTGTGGATATCAAGTGGCTT
    GAAACACTAGCTAAACGTGAATTTATCAACGGCAT
    GGCAGAAGTGATCAAGACAGCGTGCATCTGGAACG
    CTGATGAATTTACTCGTCTCGAATCCAACGCGTCA
    CTGTTCCTAAACGTAGTAAATGGTGCGAAAAATGT
    AAAGGTGACTAACCAGCTGACGAACGAGATAGATG
    AGATCAGCAACACGGATATTGAAGCCATGTTGGAC
    CATACTTATAAACTGGTATTAGAGAGTATTAAGGT
    TAAAGCGGAGGTGGTAAGCAGCGATGAAAGGGAGA
    GCAGTCTTAGGAACCTTTTAAACTTCGGGCATAGC
    ATAGGTCACGCGTATGAAGCCATACTGACACCCCA
    GGCTTTACATGGAGAGTGCGTATCCATCGGCATGG
    TAAAAGAAGCAGAACTATCAAGGTATTTTGGGATA
    CTTTCTCCGACCCAGGTGGCGCGTCTAAGCAAAAT
    TCTAGTTGCGTACGGATTGCCCGTTAGCCCCGATG
    AGAAATGGTTTAAAGAGCTTACACTTCATAAGAAG
    ACACCCTTGGACATACTGCTAAAGAAGATGAGCAT
    CGACAAGAAAAATGAAGGAAGCAAGAAGAAGGTCG
    TAATCCTAGAGTCTATCGGCAAATGTTACGGAGAC
    TCAGCTCAGTTTGTTTCAGACGAAGACTTACGTTT
    TATATTGACAGATGAAACACTAGTATATCCTTTTA
    AGGATATTCCCGCTGATCAGCAGAAAGTCGTGATT
    CCACCCGGAAGTAAATCAATAAGCAATCGTGCTTT
    AATCTTAGCAGCTCTGGGGGAGGGACAGTGCAAGA
    TCAAGAACCTATTACACTCCGACGACACCAAACAT
    ATGCTGACCGCAGTCCACGAGTTAAAAGGTGCTAC
    CATCAGTTGGGAGGATAACGGAGAAACAGTGGTCG
    TAGAGGGCCATGGCGGGAGCACTCTATCGGCTTGT
    GCTGATCCCTTATACTTAGGCAACGCGGGGACGGC
    GAGTAGATTCTTAACATCACTGGCGGCACTAGTGA
    ACAGTACATCCTCCCAAAAGTATATCGTACTAACA
    GGCAACGCAAGGATGCAGCAACGTCCGATAGCGCC
    CCTTGTTGACAGCTTACGTGCTAACGGGACAAAGA
    TCGAGTACTTGAACAACGAAGGTTCTTTGCCGATC
    AAAGTGTACACTGATTCTGTATTTAAAGGCGGCCG
    TATTGAGTTGGCTGCGACAGTTAGTTCCCAATACG
    TGAGCAGTATCCTGATGTGTGCGCCTTACGCAGAA
    GAGCCCGTGACTTTAGCTTTGGTAGGTGGGAAACC
    GATCAGTAAACTATACGTTGATATGACAATTAAGA
    TGATGGAAAAGTTCGGCATCAATGTGGAGACCTCA
    ACCACGGAACCCTACACATACTACATTCCGAAGGG
    GCATTACATTAATCCAAGTGAGTACGTAATCGAGA
    GCGACGCTTCATCCGCTACCTATCCGTTAGCATTC
    GCCGCAATGACCGGTACCACCGTAACAGTCCCCAA
    CATCGGCTTTGAATCTCTGCAGGGCGACGCTAGAT
    TCGCAAGAGACGTCCTAAAGCCGATGGGGTGTAAA
    ATCACCCAAACGGCTACGTCTACAACCGTCAGTGG
    ACCACCCGTCGGTACGCTAAAGCCATTAAAACACG
    TTGATATGGAACCAATGACAGACGCCTTCTTAACC
    GCATGCGTTGTAGCCGCAATCAGTCATGACTCCGA
    CCCCAATTCAGCGAACACTACTACTATCGAGGGGA
    TCGCAAACCAAAGGGTTAAAGAATGCAACAGAATC
    TTAGCGATGGCTACCGAGCTGGCAAAGTTTGGAGT
    AAAGACAACAGAACTTCCCGATGGCATACAGGTCC
    ATGGGCTAAATTCCATCAAGGACCTTAAAGTCCCA
    TCTGACAGCTCAGGACCCGTCGGAGTCTGTACTTA
    TGATGACCATAGGGTTGCCATGTCATTTTCCCTTT
    TGGCTGGCATGGTAAACAGTCAGAATGAGAGAGAT
    GAAGTGGCAAACCCAGTTAGGATCTTAGAGAGGCA
    CTGCACCGGAAAGACGTGGCCAGGCTGGTGGGACG
    TTCTGCACAGCGAACTTGGAGCGAAGCTGGATGGT
    GCCGAGCCGCTAGAATGCACATCCAAAAAGAACTC
    TAAGAAGAGCGTAGTCATAATAGGCATGAGAGCTG
    CGGGCAAAACTACTATCTCTAAGTGGTGCGCAAGT
    GCGCTGGGTTACAAGTTGGTAGATTTAGATGAATT
    GTTCGAGCAGCAGCATAATAACCAATCAGTAAAAC
    AATTTGTAGTCGAGAATGGTTGGGAGAAATTCAGA
    GAGGAAGAGACCAGGATATTCAAGGAGGTTATTCA
    AAATTACGGCGACGACGGGTATGTCTTTAGCACTG
    GGGGAGGGATCGTCGAATCCGCGGAGAGCAGGAAA
    GCACTAAAGGACTTCGCCAGTTCCGGTGGGTATGT
    GCTTCACTTACATCGTGATATAGAGGAGACGATAG
    TCTTCCTACAAAGTGATCCATCCAGGCCGGCGTAT
    GTTGAGGAGATTAGGGAGGTCTGGAACCGTAGAGA
    AGGCTGGTATAAAGAATGTAGTAATTTTAGCTTTT
    TCGCACCTCACTGTAGCGCAGAGGCGGAGTTTCAA
    GCACTTAGACGTTCATTCAGTAAGTATATAGCTAC
    GATCACGGGGGTCCGTGAAATAGAGATTCCTAGTG
    GGAGGAGTGCGTTTGTATGCTTAACTTTTGACGAT
    CTAACTGAGCAAACGGAGAATCTGACGCCTATATG
    CTACGGGTGTGAAGCCGTAGAGGTGCGTGTTGATC
    ATCTTGCCAATTATTCCGCAGACTTCGTTAGCAAG
    CAATTAAGCATACTGAGAAAAGCGACCGACAGTAT
    ACCCATTATCTTCACCGTCCGTACTATGAAACAAG
    GCGGTAATTTTCCCGATGAAGAGTTCAAGACATTG
    CGTGAGTTGTACGACATAGCTCTTAAAAACGGAGT
    GGAGTTCCTTGATTTGGAACTTACTCTGCCTACAG
    ATATACAGTACGAAGTCATCAACAAGAGAGGTAAT
    ACGAAGATCATTGGGTCTCATCATGACTTCCAGGG
    TTTGTACAGCTGGGACGATGCTGAATGGGAAAACA
    GATTCAATCAGGCACTGACTCTTGACGTAGATGTG
    GTGAAATTTGTGGGTACCGCGGTGAATTTCGAGGA
    CAACTTACGTTTGGAACATTTTCGTGACACGCACA
    AAAATAAACCACTAATAGCAGTTAACATGACGTCT
    AAGGGCTCAATCAGTAGGGTACTAAATAATGTATT
    GACTCCGGTTACTTCAGACCTTTTACCGAACAGCG
    CAGCGCCTGGTCAATTGACGGTTGCACAGATTAAT
    AAAATGTATACATCTATGGGAGGAATTGAGCCTAA
    AGAGCTATTTGTGGTGGGGAAGCCAATCGGCCACT
    CAAGATCACCTATACTACACAATACTGGGTATGAG
    ATTTTGGGTCTACCTCACAAATTCGATAAATTTGA
    GACGGAAAGCGCACAATTAGTGAAGGAGAAATTGT
    TAGACGGGAACAAGAATTTCGGTGGTGCAGCGGTG
    ACCATCCCTTTAAAGCTAGACATAATGCAGTACAT
    GGATGAACTTACGGACGCTGCGAAGGTGATTGGGG
    CGGTAAACACAGTAATCCCTTTGGGTAACAAGAAA
    TTCAAGGGTGATAATACGGACTGGTTAGGGATAAG
    GAACGCACTTATAAATAATGGTGTGCCCGAGTACG
    TGGGGCATACTGCCGGACTTGTAATAGGTGCTGGT
    GGTACCAGTAGGGCGGCACTGTACGCTTTGCATAG
    CTTAGGTTGCAAGAAGATCTTTATCATCAATAGAA
    CAACTAGTAAACTGAAGCCACTGATAGAATCACTA
    CCCTCCGAGTTTAACATCATTGGAATAGAGTCTAC
    GAAATCCATCGAGGAGATTAAAGAACACGTCGGAG
    TCGCTGTTAGCTGCGTGCCTGCCGATAAGCCCTTA
    GATGACGAGCTACTGAGTAAGTTAGAACGTTTCCT
    TGTCAAGGGTGCACATGCGGCTTTCGTCCCAACAC
    TGCTAGAGGCTGCCTATAAACCCAGCGTAACACCT
    GTTATGACCATAAGTCAGGACAAGTATCAATGGCA
    CGTGGTGCCGGGTTCCCAGATGCTGGTCCATCAAG
    GTGTTGCACAATTTGAAAAATGGACTGGTTTCAAG
    GGGCCCTTCAAAGCCATATTTGACGCCGTGACTAA
    AGAGTAA
    (Saccharomycescerevisiae (ARO2 gene))
    SEQ ID NO: 28
    ATGTCCACATTCGGTAAACTTTTCCGTGTCACTAC
    ATACGGCGAGTCACACTGCAAATCTGTGGGGTGCA
    TAGTAGACGGCGTTCCGCCGGGCATGAGTTTAACC
    GAAGCGGACATTCAACCTCAGCTTACCCGTAGGAG
    GCCCGGTCAGAGCAAGTTATCCACCCCGAGGGACG
    AAAAGGACCGTGTAGAGATCCAAAGCGGAACGGAA
    TTTGGGAAGACACTTGGTACGCCTATCGCTATGAT
    GATTAAAAACGAGGATCAACGTCCGCACGATTACT
    CCGACATGGACAAGTTCCCTAGGCCGAGTCACGCC
    GATTTTACGTACTCAGAGAAATACGGAATAAAAGC
    CTCCAGCGGTGGGGGCCGTGCTTCCGCGAGAGAAA
    CCATTGGAAGAGTAGCATCCGGTGCAATAGCAGAG
    AAGTTCCTAGCACAGAACTCAAATGTTGAAATTGT
    CGCTTTCGTCACGCAAATAGGTGAGATCAAGATGA
    ACCGTGACAGTTTCGACCCAGAATTTCAACACCTT
    CTAAATACAATTACGAGGGAGAAGGTAGATAGCAT
    GGGTCCAATAAGATGCCCCGACGCTTCCGTCGCGG
    GATTGATGGTGAAGGAAATTGAAAAATATCGTGGG
    AACAAGGATTCTATTGGGGGTGTAGTAACTTGCGT
    AGTCAGAAATCTACCTACAGGGTTGGGTGAACCGT
    GTTTTGACAAACTGGAGGCGATGCTGGCACATGCC
    ATGTTATCCATACCAGCAAGTAAAGGATTTGAAAT
    AGGATCTGGCTTCCAGGGTGTAAGCGTACCAGGAA
    GCAAACACAATGATCCCTTTTACTTTGAAAAAGAG
    ACTAACCGTCTTCGTACAAAGACAAACAACTCCGG
    TGGGGTGCAAGGGGGCATCTCTAATGGTGAGAACA
    TTTACTTTTCCGTACCATTTAAGAGCGTGGCTACA
    ATAAGCCAAGAGCAAAAGACCGCAACTTACGATGG
    AGAAGAAGGAATCCTCGCAGCTAAGGGTAGGCACG
    ATCCTGCGGTCACACCGCGTGCAATTCCCATAGTG
    GAAGCTATGACCGCCCTAGTACTAGCAGATGCGTT
    ACTAATACAGAAAGCCAGGGATTTTTCTAGGTCAG
    TCGTACATTAA
    (Saccharomycescerevisiae (ARO3 gene)) 
    SEQ ID NO: 29
    ATGTTCATCAAGAATGACCATGCTGGTGATAGAAA
    GAGACTAGAGGACTGGCGTATAAAGGGTTATGACC
    CTCTAACTCCGCCTGATTTGCTACAGCACGAGTTT
    CCTATATCAGCAAAAGGGGAAGAAAATATCATCAA
    GGCTCGTGATAGTGTATGTGATATACTGAACGGAA
    AGGATGACAGACTTGTGATAGTAATTGGACCCTGT
    TCTCTGCATGATCCGAAGGCGGCCTACGACTATGC
    CGACAGATTAGCCAAAATATCCGAAAAGCTGTCAA
    AAGATCTTTTAATTATCATGCGTGCATACCTAGAG
    AAGCCTCGTACAACCGTTGGATGGAAAGGGTTGAT
    AAACGACCCGGATATGAACAATAGTTTTCAGATTA
    ATAAAGGCCTTCGTATAAGCCGTGAGATGTTTATA
    AAACTAGTTGAGAAATTACCTATTGCAGGAGAAAT
    GCTTGACACGATTTCCCCTCAGTTCTTATCTGACT
    GTTTCTCACTAGGTGCAATTGGTGCTAGGACTACC
    GAGTCACAGTTACATCGTGAACTGGCCAGCGGTCT
    GTCTTTCCCCATTGGCTTTAAAAATGGTACCGATG
    GTGGCCTTCAAGTAGCAATTGATGCTATGAGAGCT
    GCGGCCCACGAACACTACTTTTTGTCTGTGACCAA
    ACCTGGCGTAACAGCGATTGTGGGAACTGAAGGGA
    ACAAGGACACCTTCCTAATCCTGAGAGGGGGCAAG
    AACGGGACTAATTTTGACAAGGAGTCAGTTCAAAA
    CACTAAGAAGCAATTGGAGAAGGCGGGCCTTACTG
    ACGATTCTCAGAAGAGAATCATGATAGACTGCAGC
    CATGGCAACTCAAATAAAGATTTCAAAAATCAACC
    CAAAGTCGCCAAGTGTATCTACGATCAACTAACCG
    AAGGAGAAAATAGTTTATGCGGGGTGATGATAGAG
    AGTAATATAAACGAAGGAAGACAGGATATTCCTAA
    GGAAGGCGGAAGAGAGGGTCTGAAGTACGGGTGTT
    CTGTGACAGACGCTTGCATAGGATGGGAGAGCACG
    GAACAGGTTTTGGAGCTGCTGGCAGAAGGGGTGCG
    TAATAGAAGGAAAGCCTTAAAGAAGTAA
    (Saccharomycescerevisiae (ARO4 K2229L gene))
    SEQ ID NO: 30
    ATGAGCGAATCTCCGATGTTCGCCGCAAACGGCAT
    GCCTAAGGTAAATCAAGGGGCCGAGGAGGACGTGA
    GAATATTAGGTTATGACCCGCTTGCCAGTCCTGCA
    TTGCTTCAGGTACAGATTCCAGCAACGCCAACGTC
    CTTAGAAACAGCAAAAAGGGGACGTCGTGAAGCTA
    TAGACATCATCACTGGCAAGGACGACCGTGTCCTA
    GTAATAGTTGGTCCGTGCTCTATCCATGACCTTGA
    GGCTGCACAGGAGTATGCACTAAGGTTGAAGAAAT
    TGTCTGATGAACTGAAAGGTGATCTTAGTATAATC
    ATGCGTGCATATTTAGAGAAACCGCGTACGACGGT
    AGGCTGGAAAGGGCTAATTAACGATCCGGATGTGA
    ATAATACCTTTAACATCAACAAGGGTCTACAGAGT
    GCGCGTCAGTTATTCGTGAACTTAACAAATATCGG
    ACTGCCGATAGGCTCCGAGATGCTGGACACGATAT
    CTCCCCAGTATTTGGCTGACCTTGTTTCTTTTGGA
    GCTATAGGTGCAAGGACTACTGAGAGTCAGTTACA
    TAGAGAGTTGGCATCAGGACTTAGCTTCCCTGTAG
    GATTTAAGAACGGTACAGACGGCACTCTTAATGTC
    GCGGTCGATGCCTGCCAGGCAGCCGCCCATTCACA
    TCATTTTATGGGAGTGACATTACACGGGGTGGCCG
    CTATCACAACGACTAAAGGGAATGAGCACTGTTTT
    GTTATCCTTAGAGGAGGAAAGAAAGGTACGAATTA
    TGATGCGAAAAGTGTAGCAGAGGCCAAAGCGCAAC
    TTCCTGCCGGTTCAAACGGACTTATGATTGACTAT
    TCCCATGGAAACTCAAATAAGGACTTTAGGAATCA
    GCCAAAAGTTAACGATGTGGTATGCGAACAGATCG
    CGAACGGTGAAAATGCGATTACGGGTGTTATGATC
    GAGTCAAATATAAATGAAGGTAACCAAGGTATCCC
    GGCAGAGGGCAAAGCGGGCCTGAAGTACGGTGTAT
    CTATTACGGATGCCTGTATAGGTTGGGAGACAACC
    GAAGACGTCCTAAGGAAACTTGCCGCCGCGGTTAG
    ACAGAGACGTGAAGTCAATAAGAAGTAA
    (Escherichiacoli (AROL gene))
    SEQ ID NO: 31
    ATGACCCAGCCATTATTTCTGATCGGTCCTCGTGG
    GTGCGGGAAAACGACGGTTGGCATGGCCTTAGCTG
    ACAGTTTGAATCGTAGATTCGTGGACACCGACCAG
    TGGCTACAGTCTCAGCTTAACATGACGGTGGCCGA
    AATTGTAGAACGTGAAGAATGGGCTGGTTTTCGTG
    CAAGAGAAACAGCCGCATTGGAAGCTGTGACGGCG
    CCTTCAACGGTGATAGCTACGGGAGGTGGTATTAT
    TTTGACCGAATTTAATAGGCACTTCATGCAGAATA
    ATGGCATAGTGGTTTACCTATGCGCTCCTGTGTCT
    GTCTTGGTAAACCGTTTGCAAGCCGCACCAGAAGA
    AGACTTGCGTCCAACCCTGACGGGGAAGCCACTGT
    CTGAGGAAGTGCAAGAGGTACTGGAGGAAAGGGAC
    GCTCTATACCGTGAGGTGGCTCACATCATAATTGA
    CGCTACGAATGAGCCATCACAGGTAATTTCTGAGA
    TCCGTTCAGCGTTGGCCCAAACCATCAATTGTTAA
    (Saccharomycescerevisiae (TRP1 gene))
    SEQ ID NO: 32
    ATGTCAGTGATTAACTTTACAGGCTCCTCAGGTCC
    CTTGGTCAAGGTCTGCGGCTTGCAATCAACAGAGG
    CCGCTGAATGCGCCCTAGACTCAGATGCAGACCTT
    TTAGGCATCATCTGTGTCCCCAACAGAAAGCGTAC
    TATTGATCCTGTTATTGCGCGTAAGATCAGTTCTT
    TGGTCAAGGCGTATAAGAACTCCTCAGGAACCCCC
    AAGTATCTGGTAGGGGTATTCAGGAATCAACCTAA
    AGAAGACGTCTTGGCCCTAGTTAATGACTACGGCA
    TAGACATAGTCCAGTTGCACGGAGACGAAAGCTGG
    CAAGAATATCAGGAATTTTTGGGGCTGCCGGTTAT
    AAAAAGGCTGGTTTTCCCTAAGGACTGTAACATAC
    TGTTATCAGCCGCATCACAGAAGCCGCATTCCTTT
    ATACCTCTTTTCGACTCCGAGGCCGGAGGCACTGG
    TGAATTACTGGACTGGAACAGCATTTCAGATTGGG
    TAGGGAGGCAGGAGAGCCCAGAATCTCTTCATTTT
    ATGTTGGCAGGGGGCCTTACGCCGGAAAATGTTGG
    AGATGCATTGAGGTTGAACGGAGTTATAGGTGTGG
    ATGTCAGTGGTGGGGTTGAAACGAATGGTGTTAAA
    GACAGCAACAAAATAGCAAATTTTGTCAAGAATGC
    CAAAAAGTAA
    (Saccharomycescerevisiae (TRP2 S76L gene))
    SEQ ID NO: 33
    ATGACGGCGAGCATTAAAATTCAGCCAGACATTGA
    CAGTTTAAAGCAGTTGCAGCAACAGAATGACGACT
    CTTCCATTAACATGTATCCCGTGTATGCGTATCTG
    CCTTCTTTGGATTTGACACCTCACGTTGCTTACTT
    AAAGTTAGCTCAACTTAATAATCCAGATAGAAAGG
    AGTCTTTCTTACTTGAAAGTGCTAAGACCAATAAT
    GAGCTGGACAGATATCTTTTCATAGGGATCAGTCC
    AAGGAAGACCATTAAGACCGGGCCCACTGAAGGCA
    TTGAGACTGACCCATTAGAAATCCTTGAAAAAGAA
    ATGTCTACTTTCAAAGTCGCCGAAAACGTCCCAGG
    CCTTCCCAAATTAAGCGGCGGGGCGATAGGTTACA
    TATCATACGACTGTGTACGTTACTTCGAACCCAAG
    ACTAGGCGTCCCTTGAAAGATGTGCTTAGGTTACC
    AGAGGCGTACTTGATGCTTTGTGACACGATAATCG
    CATTTGACAATGTCTTCCAAAGGTTTCAAATTATT
    CACAATATTAACACAAACGAAACGTCTTTGGAGGA
    AGGATACCAGGCGGCTGCGCAGATAATCACGGATA
    TTGTATCTAAGTTGACAGACGACAGCTCCCCCATT
    CCGTACCCGGAGCAACCCCCTATCAAACTAAACCA
    AACCTTTGAATCCAACGTAGGCAAAGAGGGGTATG
    AAAATCACGTCTCCACTCTCAAAAAGCACATAAAG
    AAAGGTGACATAATCCAAGGTGTGCCCAGCCAGAG
    AGTGGCGAGGCCTACATCTTTACATCCATTCAACA
    TATATAGGCATCTTAGAACCGTGAACCCATCACCT
    TATCTATTTTACATAGACTGCCTAGATTTCCAGAT
    AATAGGGGCTAGTCCCGAATTGCTGTGTAAATCAG
    ATTCAAAGAATCGTGTTATTACACACCCCATAGCT
    GGCACAGTCAAGAGGGGTGCTACCACTGAGGAAGA
    TGACGCTCTGGCAGATCAGCTACGTGGTTCTTTGA
    AAGATAGGGCTGAGCATGTTATGCTGGTTGACTTA
    GCAAGAAACGACATCAATCGTATATGCGATCCCCT
    AACGACTTCCGTTGACAAACTTTTGACCATTCAGA
    AGTTCAGCCACGTACAGCACTTAGTCTCTCAGGTC
    TCTGGCGTCCTAAGGCCTGAGAAAACTCGTTTCGA
    TGCATTCAGAAGCATATTTCCCGCGGGTACAGTGA
    GTGGGGCCCCAAAGGTGCGTGCAATGGAGCTTATA
    GCCGAGCTAGAAGGCGAGCGTAGGGGAGTGTACGC
    AGGGGCCGTAGGCCATTGGTCTTATGACGGCAAGA
    CCATGGATAATTGTATTGCACTAAGGACCATGGTC
    TATAAAGATGGGATTGCATACTTGCAGGCAGGAGG
    TGGGATTGTCTATGACAGCGATGAGTACGATGAGT
    ATGTAGAAACAATGAATAAAATGATGGCGAATCAT
    TCCACGATAGTGCAGGCGGAGGAGTTATGGGCGGA
    TATTGTGGGTAGTGCATAA
    (Saccharomycescerevisiae (TRP3 gene))
    SEQ ID NO: 34
    ATGTCTGTCCACGCAGCCACCAACCCGATAAATAA
    GCATGTCGTTCTGATTGATAATTACGACTCCTTCA
    CGTGGAATGTTTATGAGTATCTTTGCCAGGAGGGA
    GCGAAGGTTAGCGTTTACCGTAATGACGCTATCAC
    GGTCCCAGAAATTGCAGCACTGAATCCCGATACCC
    TTCTGATATCACCAGGCCCGGGCCATCCCAAGACA
    GATTCTGGTATTAGCAGAGATTGCATCAGATACTT
    CACTGGAAAAATTCCAGTTTTTGGGATATGTATGG
    GGCAGCAATGCATGTTTGACGTGTTTGGCGGGGAA
    GTGGCTTATGCGGGTGAAATAGTGCACGGAAAGAC
    TAGTCCCATATCCCATGATAACTGCGGTATCTTTA
    AGAATGTCCCCCAGGGTATTGCAGTTACAAGATAT
    CATAGCTTGGCTGGCACTGAAAGTAGTCTGCCTAG
    CTGCCTAAAGGTGACTGCCTCTACTGAAAACGGGA
    TAATCATGGGGGTAAGGCACAAGAAGTACACCGTC
    GAGGGGGTGCAATTCCACCCAGAGAGTATTTTAAC
    CGAAGAAGGACATCTAATGATCCGTAATATTCTTA
    ATGTTTCTGGCGGAACGTGGGAGGAAAATAAATCA
    AGCCCATCCAATTCCATCCTAGATAGGATATACGC
    CAGGCGTAAAATTGACGTAAACGAACAGTCAAAGA
    TTCCCGGTTTCACCTTTCAGGACTTACAATCTAAC
    TATGATCTTGGCCTTGCCCCGCCTCTGCAAGATTT
    TTATACCGTGCTGAGCAGTAGTCATAAGAGGGCTG
    TGGTCCTAGCGGAGGTGAAGCGTGCCTCCCCTAGC
    AAAGGTCCAATCTGCCTGAAGGCCGTTGCTGCTGA
    ACAAGCCCTTAAATATGCTGAGGCTGGGGCGAGTG
    CAATTAGCGTTCTAACAGAACCCCACTGGTTCCAC
    GGGAGCCTTCAAGACCTTGTGAATGTAAGAAAGAT
    CTTGGATCTAAAATTTCCGCCAAAAGAGAGACCCT
    GCGTGCTTAGGAAAGAGTTTATATTTTCCAAATAC
    CAAATATTGGAGGCACGTCTAGCTGGTGCAGATAC
    TGTCCTTTTGATTGTAAAGATGTTGTCCCAACCAT
    TACTGAAAGAGCTATATAGTTACTCAAAGGATTTA
    AACATGGAGCCGTTAGTGGAAGTAAATAGCAAGGA
    GGAGCTACAACGTGCCCTGGAAATTGGTGCCAAGG
    TTGTTGGAGTTAACAATCGTGACTTGCATTCCTTC
    AACGTAGACTTGAATACAACAAGTAATTTGGTCGA
    ATCTATCCCAAAAGATGTGCTGTTGATTGCACTTT
    CCGGTATCACAACACGTGATGACGCCGAAAAGTAT
    AAAAAGGAGGGGGTGCACGGGTTTTTGGTGGGTGA
    GGCGTTAATGAAATCTACAGATGTAAAGAAGTTTA
    TTCATGAGCTGTGCGAATAA
    (Saccharomycescerevisiae (TRP4 gene))
    SEQ ID NO: 35
    ATGAGCGAAGCTACTCTATTAAGTTATACCAAAAA
    GCTACTAGCAAGCCCACCTCAGCTTAGTTCCACCG
    ACCTACACGATGCACTACTTGTCATCCTAAGTCTA
    CTTCAGAAGTGCGACACCAATTCTGATGAGTCCTT
    GTCTATTTATACGAAGGTGTCTTCCTTTTTAACAG
    CCCTAAGGGTGACTAAGTTAGATCATAAGGCGGAA
    TATATTGCCGAGGCTGCAAAAGCAGTTTTGCGTCA
    CTCAGATCTGGTCGATCTACCTTTACCTAAAAAGG
    ATGAGCTGCATCCTGAAGATGGTCCTGTTATCTTG
    GACATTGTGGGTACTGGGGGTGATGGACAGAATAC
    CTTTAACGTGTCAACGTCAGCCGCTATTGTGGCCT
    CAGGTATTCAGGGACTGAAGATTTGCAAACACGGA
    GGTAAAGCATCTACCTCAAACAGCGGAGCTGGAGA
    TCTGATTGGGACATTGGGATGCGATATGTTCAAAG
    TGAATAGTAGCACAGTCCCCAAATTGTGGCCAGAC
    AATACATTTATGTTCTTATTGGCTCCATTCTTTCA
    TCATGGGATGGGTCATGTAAGCAAGATTCGTAAGT
    TTCTTGGAATACCTACGGTATTTAACGTATTGGGG
    CCGCTGTTACACCCCGTATCCCATGTGAATAAGAG
    GATACTTGGAGTGTATTCAAAAGAGTTGGCGCCAG
    AATATGCGAAGGCAGCAGCCTTGGTCTATCCAGGG
    TCAGAAACGTTTATTGTGTGGGGCCATGTTGGGCT
    TGACGAGGTGAGCCCCATAGGAAAGACTACCGTGT
    GGCACATCGATCCGACAAGCTCAGAACTAAAGTTG
    AAGACCTTCCAGCTGGAGCCATCTATGTTCGGTCT
    GGAGGAGCACGAGCTGAGTAAATGCGCCTCATATG
    GACCTAAGGAGAATGCTCGTATATTAAAGGAGGAA
    GTCCTTTCCGGCAAATACCACCTAGGCGACAATAA
    TCCAATATATGATTACATTCTGATGAATACTGCAG
    TATTATACTGCCTGTCCCAAGGGCACCAAAACTGG
    AAGGAAGGTATTATCAAAGCCGAGGAGTCAATTCA
    CAGCGGGAATGCCTTGAGATCGCTAGAACATTTCA
    TTGATTCAGTATCTTCCCTTTAA
    (Saccharomycescerevisiae (TAT2 gene))
    SEQ ID NO: 36
    ATGACCGAAGATTTCATCAGTAGCGTCAAAAGGTC
    AAATGAAGAGCTTAAAGAGAGAAAATCTAATTTTG
    GGTTTGTAGAGTACAAGTCAAAACAACTTACCTCC
    AGTAGCTCACACAACTCCAACTCTTCACACCATGA
    TGACGACAACCAGCACGGTAAAAGAAACATCTTTC
    AGCGTTGTGTGGATTCTTTTAAATCCCCTCTGGAT
    GGGTCTTTCGACACCTCCAATCTGAAAAGAACACT
    GAAACCTCGTCATTTAATAATGATCGCAATAGGAG
    GTAGTATAGGTACTGGTCTTTTCGTGGGTTCAGGG
    AAGGCTATAGCGGAAGGCGGACCACTTGGCGTTGT
    GATCGGATGGGCCATTGCGGGTAGCCAAATAATAG
    GTACTATACATGGGTTAGGAGAGATCACGGTAAGA
    TTTCCAGTAGTCGGTGCGTTTGCCAACTACGGCAC
    CCGTTTCTTGGACCCGAGCATTAGTTTTGTAGTCT
    CCACTATATACGTGCTACAGTGGTTCTTTGTCCTA
    CCCCTAGAGATTATTGCTGCGGCGATGACCGTGCA
    ATACTGGAACAGTTCTATCGATCCGGTAATATGGG
    TCGCAATTTTCTATGCCGTCATCGTCTCAATCAAT
    TTGTTTGGAGTTAGGGGTTTCGGAGAAGCTGAATT
    CGCCTTCTCAACTATTAAGGCAATCACTGTCTGTG
    GCTTCATAATCTTATGTGTAGTCTTGATCTGCGGC
    GGAGGACCCGATCACGAATTCATTGGTGCTAAATA
    CTGGCATGATCCTGGCTGCCTGGCAAACGGGTTTC
    CTGGAGTCTTGAGTGTCCTTGTCGTTGCGTCATAC
    AGCCTAGGAGGCATAGAAATGACTTGCTTAGCCTC
    TGGGGAAACGGACCCAAAGGGACTTCCCTCAGCTA
    TAAAACAGGTTTTCTGGCGTATTTTGTTTTTCTTC
    TTAATTTCTTTAACTCTAGTGGGATTTTTAGTTCC
    TTACACCAACCAAAATCTACTAGGTGGCTCCTCTG
    TCGATAATAGTCCCTTCGTTATCGCGATTAAGCTA
    CACCATATCAAAGCTCTTCCGTCTATTGTTAACGC
    AGTTATCCTTATTTCCGTGCTATCCGTGGGTAACA
    GTTGCATCTTTGCCAGCTCCAGAACTCTGTGTAGC
    ATGGCACATCAAGGACTGATACCGTGGTGGTTCGG
    CTATATTGACAGAGCTGGCAGACCCCTGGTTGGGA
    TTATGGCCAATTCTCTTTTCGGCTTATTGGCGTTC
    CTTGTTAAATCTGGCTCCATGAGTGAGGTGTTTAA
    TTGGCTGATGGCTATAGCCGGACTGGCGACATGTA
    TTGTGTGGTTATCTATAAATCTTTCCCATATAAGA
    TTCCGTCTTGCAATGAAGGCCCAAGGAAAGTCCCT
    GGATGAACTTGAATTCGTAAGCGCGGTTGGTATAT
    GGGGATCTGCTTATTCCGCACTTATCAATTGCTTA
    ATACTTATTGCTCAATTTTATTGCTCTTTATGGCC
    AATCGGGGGTTGGACATCCGGAAAAGAGAGGGCAA
    AGATTTTCTTTCAGAATTATCTTTGCGCCCTGATT
    ATGTTATTTATATTCATCGTCCATAAGATCTATTA
    TAAATGTCAAACGGGAAAGTGGTGGGGTGTTAAAG
    CTCTGAAGGACATCGACCTAGAGACCGACAGGAAG
    GACATAGACATCGAAATAGTTAAACAAGAAATCGC
    TGAAAAGAAGATGTATTTGGACTCCAGACCTTGGT
    ACGTGAGGCAGTTTCATTTTTGGTGCTAA

Claims (9)

1-21. (canceled)
22. A recombinant host organism comprising:
a plurality of cells transfected by a non-natural gene expressed in the recombinant host organism;
wherein the recombinant host organism is a fungal species selected from the group consisting of Schizosaccharomyces cerevisiae, Schizosaccharomyces japonicus, Schizosaccharomyces pombe, Schizosaccharomyces cryophilus, Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces dobzhanskii, and Yarrowia lipolytica;
wherein the non-natural gene is selected from a group consisting of PsiD, PsiH, PsiK, and PsiM, wherein:
PsiD encodes an L-tryptophan decarboxylase comprising an amino acid sequence having at least 90% identity to any one of amino acid sequences set forth in SEQ ID NO:14-SEQ ID NO:16;
PsiH encodes a tryptamine 4-monooxygenase comprising an amino acid sequence having at least 90% identity to any one of amino acid sequences set forth in SEQ ID NO:17-SEQ ID NO:19;
PsiK encodes a 4-hydroxytryptamine kinase comprising an amino acid sequence having at least 90% identity to any one of amino acid sequences set forth in SEQ ID NO:20 or SEQ ID NO:21; and
PsiM encodes a methyl transferase comprising an amino acid sequence having at least 90% identity to any one of amino acid sequences set forth in SEQ ID NO:22-SEQ ID NO:26.
23. The recombinant host organism of claim 22, wherein
the L-tryptophan decarboxylase comprises any one of amino acid sequences set forth in SEQ ID NO:14-SEQ ID NO:16;
the tryptamine 4-monooxygenase comprises any one of amino acid sequences set forth in SEQ ID NO:17-SEQ ID NO:19;
the 4-hydroxytryptamine kinase comprises any one of amino acid sequences set forth in SEQ ID NO:20 or SEQ ID NO:21; and
the methyl transferase comprises any one of amino acid sequences set forth in SEQ ID NO:22-SEQ ID NO:26.
24. The recombinant host organism of claim 22, comprising PsiD, PsiH, PsiK and PsiM, wherein the organism synthesizes psilocybin.
25. The recombinant host organism of claim 22, further comprising at least one non-natural gene selected from the group consisting of: SEQ ID NO:27-SEQ ID NO:35.
26. The recombinant host organism of claim 22, further comprising a recombinant transporter protein that is codon optimized for expression in the recombinant host organism.
27. The recombinant host organism of claim 26, wherein the recombinant transporter protein comprises SEQ ID NO:36.
28. The recombinant host organism of claim 22, growing in a medium comprising glucose, galactose, sucrose, fructose, molasses, or any combination thereof.
29. A method, the method comprising:
transfecting a plurality of cells in a recombinant host organism with a set of genes comprising PsiD, PsiH, PsiK and PsiM, creating the recombinant host organism of claim 22; and
synthesizing psilocybin in the recombinant host organism.
US17/878,858 2019-11-15 2022-08-01 Biosynthetic production of psilocybin and related intermediates in recombinant organisms Abandoned US20220389467A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/878,858 US20220389467A1 (en) 2019-11-15 2022-08-01 Biosynthetic production of psilocybin and related intermediates in recombinant organisms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962936387P 2019-11-15 2019-11-15
US17/099,539 US11441164B2 (en) 2019-11-15 2020-11-16 Biosynthetic production of psilocybin and related intermediates in recombinant organisms
US17/878,858 US20220389467A1 (en) 2019-11-15 2022-08-01 Biosynthetic production of psilocybin and related intermediates in recombinant organisms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/099,539 Continuation US11441164B2 (en) 2019-11-15 2020-11-16 Biosynthetic production of psilocybin and related intermediates in recombinant organisms

Publications (1)

Publication Number Publication Date
US20220389467A1 true US20220389467A1 (en) 2022-12-08

Family

ID=75909886

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/099,539 Active US11441164B2 (en) 2019-11-15 2020-11-16 Biosynthetic production of psilocybin and related intermediates in recombinant organisms
US17/878,858 Abandoned US20220389467A1 (en) 2019-11-15 2022-08-01 Biosynthetic production of psilocybin and related intermediates in recombinant organisms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US17/099,539 Active US11441164B2 (en) 2019-11-15 2020-11-16 Biosynthetic production of psilocybin and related intermediates in recombinant organisms

Country Status (3)

Country Link
US (2) US11441164B2 (en)
CA (1) CA3155976A1 (en)
WO (1) WO2021097452A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514682A (en) 2018-03-08 2021-06-17 ニュー アトラス バイオテクノロジーズ エルエルシー How to produce tryptamine
JP2022550463A (en) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス, インコーポレイテッド Genetic engineering of fungi to modulate tryptamine expression
EP4153564A4 (en) 2020-05-19 2024-06-19 Cybin IRL Limited Deuterated tryptamine derivatives and methods of use
CN113371848B (en) * 2021-06-29 2022-09-16 内蒙古阜丰生物科技有限公司 Comprehensive treatment process of amino acid wastewater
WO2023015279A1 (en) * 2021-08-05 2023-02-09 Miami University Methods for the production of methylated tryptamine derivatives, intermediates or side products
WO2023081829A2 (en) * 2021-11-05 2023-05-11 Miami University Methods for the improved production of psilocybin and intermediates or side products through enzyme optimization
AU2022381203A1 (en) * 2021-11-05 2024-05-16 Miami University Methods for the production of tryptophans, tryptamines, intermediates, side products and derivatives
CA3241326A1 (en) 2021-12-03 2023-06-08 Medicinal Genomics Corporation Psilocybe assay
EP4223883A1 (en) 2022-02-02 2023-08-09 Infinit Biosystems Process for producing tryptamines
WO2024059493A1 (en) 2022-09-13 2024-03-21 Medicinal Genomics Corporation Psilocybe assay

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809059B2 (en) * 2007-09-21 2014-08-19 Basf Plant Science Gmbh Plants with increased yield
CN103987840A (en) 2011-08-08 2014-08-13 国际香料香精公司 Compositions and methods for the biosynthesis of vanillin or vanillin beta-D-glucoside
US20170159047A9 (en) 2014-08-29 2017-06-08 Massachusetts Institute Of Technology Composability and design of parts for large-scale pathway engineering in yeast
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
JP2021514682A (en) * 2018-03-08 2021-06-17 ニュー アトラス バイオテクノロジーズ エルエルシー How to produce tryptamine
FI129102B (en) * 2018-03-19 2021-07-15 Teknologian Tutkimuskeskus Vtt Oy Heterologous production of psilocybin
US20220372494A1 (en) 2019-10-28 2022-11-24 Miami University Methods for the production of psilocybin and intermediates or side products

Also Published As

Publication number Publication date
WO2021097452A2 (en) 2021-05-20
US11441164B2 (en) 2022-09-13
CA3155976A1 (en) 2021-05-20
US20210147888A1 (en) 2021-05-20
WO2021097452A3 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
US20220389467A1 (en) Biosynthetic production of psilocybin and related intermediates in recombinant organisms
US11136293B2 (en) Processes for the production of tryptamines
Zhang et al. Integration of ARTP mutagenesis with biosensor-mediated high-throughput screening to improve L-serine yield in Corynebacterium glutamicum
Liu et al. Biosensor-based evolution and elucidation of a biosynthetic pathway in Escherichia coli
TW202039823A (en) Genetically modified microorganism and method both for producing nicotinamide derivative, and vector for use in same
US9512449B2 (en) Method for producing phenol from renewable resources by fermentation
EP2889378B1 (en) Method for producing hydroxy-l-lysine employing an l-lysine hydroxylase and method for producing hydroxy-l-pipecolic acid
KR20120088753A (en) Microorganisms for the production of aniline
CN108463555A (en) The method for producing benzaldehyde
Kuivanen et al. Engineering of Saccharomyces cerevisiae for anthranilate and methyl anthranilate production
Jiang et al. High-yield ectoine production in engineered Corynebacterium glutamicum by fine metabolic regulation via plug-in repressor library
Tsunematsu et al. Enzymatic Amide Tailoring Promotes Retro‐Aldol Amino Acid Conversion To Form the Antifungal Agent Aspirochlorine
Ren et al. Engineering substrate and energy metabolism for living cell production of cytidine‐5′‐diphosphocholine
US11932896B2 (en) Host cells and methods for producing hydroxytyrosol
Liu et al. The 138th residue of acetohydroxyacid synthase in Corynebacterium glutamicum is important for the substrate binding specificity
Xu et al. Combining precursor-directed engineering with modular designing: an effective strategy for de novo biosynthesis of L-DOPA in Bacillus licheniformis
EP3219805B1 (en) Method for manufacturing cis-5-hydroxy-l-pipecolic acid
US10920231B2 (en) Systems and methods for enhancing gene expression
Ferrer et al. L-serine biosensor-controlled fermentative production of l-tryptophan derivatives by Corynebacterium glutamicum. Biology. 2022; 11: 744
CN108424859B (en) Construction and application of gene engineering bacteria for producing citicoline
CN110241062A (en) New escherichia expression system
Peng et al. Heterologous naringenin production in the filamentous fungus Penicillium rubens
Henríquez et al. Whole cell biosynthetic activity of Komagataella phaffii (Pichia pastoris) GS115 strains engineered with transgenes encoding Chromobacterium violaceum ω‐transaminase alone or combined with native transketolase
WO2024013212A1 (en) Microbial cell factories producing thiamine
CN113817659B (en) Method for preparing beta-alanine by metabolic engineering escherichia coli fermentation

Legal Events

Date Code Title Description
AS Assignment

Owner name: CB THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VOGAN, JACOB MICHAEL;PEIFFER, LAURA FLATAUER;WADE, JAMES LEE;AND OTHERS;SIGNING DATES FROM 20210629 TO 20210715;REEL/FRAME:060690/0603

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED